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Abstract
This dissertation focuses on three types of high-dimensional genetic data: protein
sequences, DNA methylation data, and microRNA expression data. The four major
parts are presented in Chapters 2-5, respectively.
In Chapter 2, we develop a new clustering method for protein sequences. First,
we reduce the dimensionality based on entropy. Second, the sequences are clustered
using the Hamming distance vectors of chosen sites. We apply this new method to an
influenza A H3N2 HA data set, which consists of 1960 viral sequences. Our method
aggregates these sequences into 23 clusters. Based on the temporal evolution pattern
of these clusters, we find that the dominant clusters change from time to time and
are often different from the clusters housing vaccine strains.
In Chapter 3, we conduct systematic simulation studies and real data analysis
to compare the performance of seven statistical tests for equal-variance hypothesis.
Our results show that Brown-Forsythe test and trimmed-mean-based-Levene’s test
have better performance on DNA methylation data in comparison with other tests.
ii
Detection of differential DNA methylation and differential variability have re-
ceived a lot of attention in the literature. In Chapter 4, we derive the asymptotic
distribution of a joint score test (AW), proposed by Anh and Wang (2013). Further-
more, we propose three improved joint score tests, namely iAW.Lev, iAW.BF, and
iAW.TM. Systematic simulation studies show that at least one of the proposed tests
performs better than the existing tests for data with outliers or from non-normal dis-
tributions. The real data analyses demonstrate that the three proposed tests have
higher true validation rates than the existing tests.
Besides DNA methylation, microRNA regulation is another important epigenetic
mechanism. In Chapter 5, we propose a novel model-based clustering method to de-
tect differentially variable (DV) miRNAs. We impose biologically meaningful struc-
tures on covariance matrices for each cluster of miRNAs. Simulation studies show
that the proposed method performs better than other model-based methods when
miRNA expression levels are from a multivariate normal distribution. In real data
analysis, the proposed method has a higher validation rate than other methods.
iii
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1 Introduction
The innovation of statistical procedures has always been driven by the desire to
learn from emerging data. Genetic data can reflect inherited or acquired genetic
features of an organism. The analysis of genetic data can advance our understand-
ing of biological mechanisms in biological development, complex genetic disorders,
and even the evolution of a species. However, the high dimensionality of genetic
data has posed a significant challenge for scientists. With the rapid advance of se-
quencing technologies (e.g., next-generation sequencing), genetic data has exploded
in both dimensionality and complexity. For instance, one complete hemagglutinin
protein sequence in influenza contains 566 amino acid sites. Each site can have 20
possible types of amino acids and one gap. Therefore, a complete hemagglutinin
protein sequence consists of 21566 possible states. The number of possible states
is far more than the number of available sequences. During the past few years,
there have been many publications on the analysis of high-dimensional genetic data
(Boulesteix and Strimmer, 2006). Since many traditional statistical methods may
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not be applicable in the analysis of high-dimensional data, statistically rigorous and
biologically interpretable approaches are required to yield new scientific insights from
these enormous, ever-growing genetic data resources. In this dissertation, we are con-
cerned with three types of genetic data: influenza hemagglutinin protein sequences,
human DNA methylation data, and human microRNA (miRNA) expression data.
We introduce these three types of data and their related problems in the next three
sections.
1.1 Influenza hemagglutinin protein sequences
Influenza virus is a negative-stranded, segmented, and enveloped RNA virus
which incurs acute and infectious respiratory disease globally. Influenza epidemics
act as a major cause of human mortality and morbidity. They occur in the winter
months of each hemisphere every year, which is well-known as the influenza season
(or flu season). In the influenza virus family, there are two main genera: A and B.
Among them, influenza A has caused most of the flu epidemics in recent years. Based
on their surface proteins, hemagglutinin (HA) and neuraminidase (NA), influenza A
viruses can be further classified into 16 known HA and 9 known NA. The HA protein
is regarded as the primary antigenic component in the circulating influenza virus.
The occurrence of seasonal flu epidemics is highly influenced by the accumulated
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small mutations in the HA protein (antigenic drift), which allow the virus to evade
recognition of host immune systems and increase the lifetime susceptibility of the
host.
Vaccination is the most effective way to prevent or mitigate the severity of sea-
sonal flu. Each year, the formulation of seasonal flu vaccine is reviewed and some-
times updated because circulating influenza strains are continuously changing. How-
ever, high mutation rate of the seasonal influenza strains, especially on the HA pro-
tein, makes it difficult to select the most proper vaccine strains. Furthermore, some
analyses of the HA gene sequence discovered that antigenic drift of the circulating
strains from vaccine strains played an essential role in affecting the efficacy of the
vaccine (Carrat and Flahault, 2007; Boni, 2008).
Recently, investigators begin to pay attention to flu viral swarms or clusters,
which are viewed as major units driven by evolutionary forces, instead of only fo-
cusing on phylogenetic reconstruction of virus strains (Plotkin et al., 2002;  Luksza
and La¨ssig, 2014). Nevertheless, in those studies which emphasize the evolutionary
history of clades, the statistical approaches are not optimal and can be improved.
For instance, Plotkin et al. (2002) made some subjective decisions in their method-
ology and consequently, the method is not fully automatic. Moreover,  Luksza and
La¨ssig’s method has many assumptions and also substantial computation complexity.
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Therefore, a fast and effective clustering algorithm is required for flu viral sequences
to describe the flu’s temporal evolution pattern. The study of this pattern can help
us predict future mutation hot spots in influenza protein sequences and design more
effective vaccine strains.
1.2 Human DNA methylation data
DNA methylation is the most well-characterized epigenetic mechanism that reg-
ulates gene expression without changing genetic codes. In humans, methylation fre-
quently occurs by adding a methyl group to the cytosine (C) nucleotide followed by
a guanine (G) nucleotide, which is named as CpG site (Wahl et al., 2014). Aberrant
methylation patterns and levels have been shown to be associated with many diseases
such as cancer (Gopalakrishnan et al., 2008). Since DNA methylation is reversible,
it is now considered as a potential therapeutic target in cancer treatment due to its
ability to inhibit the expression of oncogenes, which can transform a normal cell into
a tumor cell in certain circumstances.
Generally, the DNA methylation level is measured as the ratio of methylated
to combined (methylated and unmethylated) levels. The definition is presented as
follows. For a given methylation site, let τi denote the original methylation value
of subject i, where i = 1, ..., n. Then τi is defined as the ratio of methylated to
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combined intensity values of signals:
τi =
Mi
Ui +Mi + e
,
where Mi and Ui are the methylated and unmethylated intensity values of subject
i, and e is a small correction term to regularize probes of low total signal intensity
(Teschendorff and Widschwendter, 2012).
Recent advances in next-generation sequencing and microarray technology allow
us to measure genome-wide methylation levels at a high resolution (Bock, 2012). A
series of Illumina Infinium Methylation platforms provide quantitative array-based
methylation measurement at the single-CpG-site level. These platforms include the
Illumina Infinium HumanMethylation27 BeadChip (HM27k), the Illumina Infinium
HumanMethylation450 BeadChip (HM450k), and the Illumina Infinium Methyla-
tionEPIC BeadChip (EPIC). All three Illumina Infinium Methylation technologies
are based on bisulfite-converted DNA. They investigate approximately 27k (HM27k),
450k (HM450k), and 850k (EPIC) CpG sites. The genomic regions targeted by the
HM27k are proximal promoter region of RefSeq genes that are well-characterized
in NCBI Reference Sequence Database and well-described cancer genes. Including
94 percent of the methylation sites of the HM27k, the HM450k covers more regions
comprising of CpG islands and related regions, bodies of RefSeq genes and functional
transcription regions, and more regulatory regions (Pidsley et al., 2016). Compared
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with the HM450k, the EPIC quantifies DNA methylation levels at more distal regu-
latory regions.
Compared with the HM27k, the HM450k and the EPIC have more interrogated
CpG sites, offering more resources for genome-wide association studies (GWAS).
However, they also bring more challenges as a result of having two different types of
chemical assays in one data, termed Infinium I and Infinium II. Infinium I assay uses
two probes (Type I probes) per CpG locus (as HM27k) to generate methylated and
unmethylated measurements. Infinium II assay uses a single probe (Type II probes)
with two different colors to differentiate methylated (green) and unmethylated signals
(red) (Wu et al., 2014; Shiah et al., 2017). The distributions of the methylation values
derived from these two assays are significantly different. Type II probes are reported
to have a reduced dynamic range and are generally less reproducible (Dedeurwaerder
et al., 2011). Along with some common noises of microarray technologies, some biases
introduced by Type II probes make the tasks of pre-processing DNA methylation data
more challenging. Hence, normalization and quality control are crucial for statistical
inference using DNA methylation data. In general, DNA methylation data should
be pre-processed and evaluated by the following steps:
(1) Normalization including background correction, within-array normalization,
and between-array normalization;
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(2) Removal of the CpG sites with low quality, including CpG sites with high
detection p-value, high missing proportion, and CpG sites residing near SNP,
etc;
(3) Principal component analysis (PCA) for detection and adjustment of batch
effects;
(4) Cell type estimation and adjustment or other adjustment.
One major goal in the analysis of methylation data is to identify disease-associated
CpG sites. Many analyses in the past have focused on the difference of mean methyla-
tion levels between the diseased and control groups. Recently, some research suggests
that methylation features detected based on variation discrepancy may also play a
crucial role in unveiling the underlying mechanisms of complex diseases (Frank, 2010;
Feinberg et al., 2010; Hansen et al., 2011; Jaffe et al., 2011; Teschendorff and Wid-
schwendter, 2012). Many DNA methylation analyses show that differentially variable
DNA methylation marks are biologically relevant to the disease of interest. However,
these investigators make the inference relying on the information from the standard
F test or Bartlett’s test (Bartlett, 1937). It is well-known that F test or Bartlett’s
test is highly sensitive to the departure of the normality assumption and the presence
of outliers. It has been reported that DNA methylation levels for different sites often
follow various distributions and contain outliers (Ahn and Wang, 2013). Therefore,
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we need robust equal-variance testing procedures, which can keep the nominal type
I error and have reasonable power even if the normality assumption is violated.
Conover et al. (1981) compared 56 equal-variance testing procedures using simu-
lation studies and found that the Brown-Forsythe test (Brown and Forsythe, 1974)
was one of the best performers in terms of robustness and testing power. Phip-
son and Oshlack (2014) compared their proposed two equal-variance tests with F
test and Bartlett’s test using simulated data generated from a Bayesian hierarchical
model and evaluated the impact of outliers on the test statistics. However, sys-
tematic comparisons among these equal-variance tests are still needed to evaluate
their performance when there are different distributions and outliers, featuring DNA
methylation data.
Since discrepancies in both mean methylation levels and methylation variabilities
can contribute to the identification of CpG sites relevant to the disease of interest,
a more efficient approach is to test equal means and equal variances simultaneously.
Some researchers have tried to construct this kind of joint tests. Littell and Folks
(1971, 1973) compared four methods of combining independent tests of hypotheses
and found that Fisher’s method is the most efficient in terms of Bahadur efficiency.
Perng and Littell (1976) suggested a joint test for two normal populations by testing
equal mean and equal variance simultaneously. The joint test is proved to have
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asymptotical optimality based on Bahadur efficiency. Zhang et al. (2012) constructed
the exact distribution of the likelihood ratio test statistic of the joint test. Chen et al.
(2014) employed a generalized exponential tilt model to derive semiparametric tests,
which could evaluate the disparities in both means and variances between diseased
and non-diseased groups. However, all these methods have parametric assumptions
on data distributions, which may be violated in DNA methylation data. Ahn and
Wang (2013) proposed a joint test to assess the discrepancies in means and variances
simultaneously. This joint test is derived from a generalized linear model and relaxes
some parametric restrictions on the data, which can be applied to DNA methylation
data with different distributions. However, Ahn and Wang (2013) did not consider
the fact that outliers are prevalent in DNA methylation data and the occurrence of
mixture structures increases a lot in the HM450k and EPIC data. Therefore, we
propose some robust joint tests to address this problem.
1.3 Human microRNA expression data
Besides DNA methylation, another important epigenetic mechanism is the regu-
lation of microRNAs (miRNAs). Ribonucleic acid (RNA) is one of the three major
biological macromolecules (DNA, RNA, and protein) that are essential for all known
forms of life. RNA can be generally classified into two categories based on whether it
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can be translated into protein (coding RNA) or not (non-coding RNA). The function-
ally important types of non-coding RNAs (ncRNAs) include transfer RNAs (tRNAs),
ribosomal RNAs (rRNAs), small RNAs (e.g., microRNAs, siRNAs), and the long
ncRNAs. The miRNAs are non-coding RNAs of about 22 nucleotides long, which
can regulate gene expression through post-transcriptional repression or target mRNA
degradation (He and Hannon, 2004; Hammond, 2015). It has been demonstrated
that miRNAs play an important role in mammalian development, maintaining tissue
homeostasis, cell cycle progression and proliferation, regulation of immune response,
and aging of the brain (Hammond, 2015; Silva Rodrigues et al., 2018; Van den Hove
et al., 2014). Aberrant miRNA expression patterns are found to be associated with
a wider range of human diseases, such as cancer (Lu et al., 2005), metabolic diseases
(Ferna´ndez-Hernando et al., 2013), Viral pathogenesis (Cullen, 2011).
The miRNA expression profiling becomes increasingly popular because miRNAs
can significantly affect many biological processes and are the promising candidates
for disease biomarkers. Three major approaches have been widely used for miRNA
profiling: quantitative reverse transcription-polymerase chain reaction (qRT-PCR),
hybridization-based methods (e.g., microarrays), and high-throughput sequencing
(i.e., RNA-seq) (Pritchard et al., 2012). These approaches have different technical
advantages, and hence can be used to achieve different research objectives. The
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qRT-PCR is a well-established method and can be used to determine absolute quan-
tification. The miRNA microarray is well established and can be easily adapted to
existing microarray workflow. RNA sequencing has high accuracy and sensitivity to
detect novel miRNAs. Ascribed to more and more comprehensive and in-depth stud-
ies of miRNAs, the public miRNA database miRBase (http://www.mirbase.org/)
contains more than 38,000 miRNA entries with detailed information on sequences
and physical structures (Kozomara and Griffiths-Jones, 2013). This information can
help us advance the understanding of the mechanisms of gene regulation and develop
novel effective miRNA-based diagnoses and therapies.
With the rapid advance of sequencing platforms, array-based technologies allow
investigators to interrogate hundreds of thousands of miRNAs simultaneously in one
experiment. Many analyses have been conducted to identify disease-associated miR-
NAs based on differential means (Bandre´s et al., 2006; Resnick et al., 2009; Bandre´s
et al., 2006). Similar to DNA methylation data, differentially variable miRNAs may
also be relevant to the disease of interest or the improvement of therapies (Mar et al.,
2011). However, to the best of our knowledge, no studies have incorporated the infor-
mation of variances because they have all focused on testing equal means in miRNA
expression data.
Generally, there are two kinds of methods used in the analyses of gene expression
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data: probe-wise approaches and model-based methods. Some common probe-wise
approaches for differential variances are F test or Bartlett’s test (Bartlett, 1937),
Brown-Forsythe test (Brown and Forsythe, 1974), and methods derived from these
tests. The probe-wise approaches are flexible and easily implemented, but they ig-
nore the correlations between gene marks and have multiple testing problems. The
model-based methods can borrow information across probes and avoid multiple test-
ing problems. Strbenac et al. (2016) used re-sampling methods and user-defined
thresholds to identify gene marks based on differential means and differential vari-
ances. This method is partially subjective due to user-defined parameters. Bar
et al. (2012, 2014) and Bar and Schifano (2018) considered differential means and
differential variances in mixture models. However, these models characterize the dis-
tributions of the summary statistics (e.g., mean, variance, or difference of means),
instead of the observed expression levels. In this dissertation, we propose a three-
component multivariate normal mixture model to fit the expression levels of miRNAs
in order to identify differentially variable miRNAs between two samples.
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2 Clustering influenza hemagglutinin protein
Sequences
In this chapter, we present a novel clustering method to aggregate the hemag-
glutinin (HA) protein sequences of flu viruses. This method has two steps: entropy-
based dimensionality reduction and clustering. We apply this method to study the
evolutionary properties of the HA component of influenza A H3N2 virus - a major
cause of seasonal flu. We show that our new method could be used to uncover HA
evolution patterns and evaluate recommended vaccine strains.
2.1 Methodology
2.1.1 Data acquisition
This study used 1960 sequences, of which 1947 sequences were directly down-
loaded from the Influenza Research Database (IRD), an online repository of influenza
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sequences, based on the criteria listed in Table 2.1. The downloaded sequences of the
H3 type HA genes were collected from locations around the globe between September
1998 and July 2012. Each of these sequences consists of 1698 nucleotides plus a stop
codon (3 nucleotides).
Table 2.1: Search criteria of HA sequences in IRD.
Option Criteria
“Data to return” protein
“Virus type” A
“Sub type” H3N2
“Select segments” HA
“Complete sequences” Complete Segments Only
“Date range” 1998 to 2012
“Host” Human
“Geographic grouping” All
Advanced options
“Month Range” Sep 1998 to July 2012
“Remove Duplicate Sequences” Yes
All other settings were kept the default or blank.
In order to explore the relationship between the collected flu sequences and rec-
ommended vaccine strains, we added recommended vaccine strains to the data set.
The vaccine sequence information was obtained from the World Health Organi-
zation (http://www.who.int/influenza/vaccines/virus/recommendations/en/). Ta-
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ble 2.2 lists the information and includes all vaccine strains used from Septem-
ber 1998 to July 2012. When we searched for vaccine strains in our downloaded
data set based on strain names, three vaccine strains called “A/Brisbane/10/2007”,
“A/Perth/16/2009”, and “A/Texas/50/2012”, were already included in the data set.
We acquired the remaining vaccine sequences separately and merged them into the
data set manually, resulting in a total of 1960 sequences in our data set.
Table 2.2: Vaccine sequences in the data set.
Stain Name Number of sequences Accession Number
A/Moscow/10/99 2 AY531035, DQ487341
A/Fujian/411/2002 2 CY088483, CY112933
A/California/7/2004 1 CY114373
A/Wisconsin/67/2005 4 CY033646, CY163936
CY114381, EU103823
A/Brisbane/10/2007 3 CY035022, CY039087
EU199366
A/Perth/16/2009 1 GQ293081
A/Victoria/361/2011 1 KC306165
A/Texas/50/2012 2 KC892248, KC892952
The resulting 1960 sequences were then translated into the corresponding amino
acids using MEGA software (Tamura et al., 2011). We translated the coding se-
quences into protein sequences instead of downloading the protein sequences directly
from IRD to avoid the handling of the ambiguous amino acid sign “B”. The transla-
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tion resulted in 566 amino acids for each of the 1960 sequences. Next, we conducted
multiple alignments on all 1960 protein sequences simultaneously using MUSCLE
software (Edgar, 2004). All sequences were neatly aligned and some of them may
have contained a few gaps. The data set can be regarded as 1960 observations (se-
quences) and 566 categorical variables (amino acid sites). Each site has 21 possible
states, 20 types of amino acids and one gap. To better analyze the data set us-
ing statistical softwares (R and Matlab), we converted the alphabetical characters
(representing amino acids) into numerical values.
Each of these 1960 sequences is related to a calendar year, country, and city of
isolation, inferred from the strain name. For the 1947 sequences that were directly
downloaded from the IRD, we can also obtain the date of isolation, which allows us
to partition the data into different influenza seasons (October 1st through September
30th).
2.1.2 Entropy-based dimensionality reduction
A dataset S with n records and p columns is a sample set of the discrete random
vector A = {a1, . . . , ap}. For each component aj, 1 ≤ j ≤ p, aj takes a value from
the state domain Ψj. For j 6= j′, Ψj is conceptually different from Ψj′ . There are a
finite number of distinct categorical values in domain(Ψj) and we denote the number
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of distinct values as |Ψj|.
For each component aj, let p(aj = k), k ∈ Ψj. The entropy of aj can be defined
as (Cover and Thomas, 2012):
H(aj) = −
∑
k∈Ψj
p(aj = k) log p(aj = k). (2.1)
Since H(aj) is estimated using the sample set S, we define the estimated entropy
as Hˆ(aj) = H(aj|S), i.e.
Hˆ(aj) =H(aj|S)
=−
∑
k∈Ψj
p(aj = k|S) log p(aj = k|S).
(2.2)
In our context, the numbers of records and columns are n = 1960 and p = 566.
Each component of the categorical vector aj, 1 ≤ j ≤ p contains 21 categorical
values, using integers 1-20 to represent the 20 types of amino acids and 21 to denote
a gap. Hence Ψj = (1, . . . , 21) and |Ψj| = 21 for j = 1, ..., 566.
To avoid subjective decision about the number of clusters, we use Hamming
distance vector (HD vector) algorithm (Zhang et al., 2006) to conduct clustering
analysis. The most time-consuming part of the HD vector algorithm is to find cluster
centers. The computational complexity is O(γ3), where γ is defined as the number of
unique sequences in the data set, which depends on M , the total number of possible
positions. Thus, we reduce the dimensionality before clustering analysis. The main
17
idea behind our dimensionality reduction is to select a smaller number (pe) of sites
based on the variabilities of the sites in the data. This is a reasonable approach,
as it is well known that parts of HA sequences are well-conserved (Stanekova´ and
Varecˇkova´, 2010). To identify the most variable (equivalently, least conserved) sites,
we use the notion of entropy. Incorporating the known information to (2.2), we
compute the entropy for each of the 566 sites as follows:
Hˆ(aj) = −
21∑
k=1
p(aj = k) log p(aj = k). (2.3)
Note that Hˆ(aj) is always positive, and large entropy indicates great variability
at a site. Sites with entropy equal to zero were removed, as there is no amino acid
variability in those sites and hence, no useful information for clustering. Sites with
entropy equal to 0.004377 (i.e. only one observation has a different state value from
the other 1959 observations) were also removed. Finally, we sorted the remaining
entropy in ascending order and used a Gaussian mixture model to cluster them
(Everitt and Hand, 1981). The algorithm results in five classes of entropies. We
identified the fifth class with the largest entropy as the selected sites to cluster all
the sequences. This class contains 62 sites (pe = 62), which allows us to reduce the
dimension to 2162. That is, our data is now made up of 62 sites (variables) and 1960
sequences (observations).
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2.1.3 Clustering categorical data
We use Hamming distance to evaluate the distance between any two sequences
(Forney, 1966). For two sequences, A = {a1, . . . , ape} and B = {b1, . . . , bpe} the
Hamming distance is defined as
ds(A,B) =
pe∑
i=1
I(ai 6= bi), (2.4)
where I(E) is the indicator function that is equal to one if E is true, and zero
otherwise. The Hamming distance between any two HA sequences is the number of
sites with different amino acids.
According to the Hamming distance vector (HD vector) algorithm (Zhang et al.,
2006), we consider a general set-up where pe nominal categorical attributes are of
interest and the jth attribute is categorized by mj (mj = |Ψj|) levels. The categorical
sample space, Ω, is defined as the collection of all possible pe-dimensional vectors of
states. For us, mj = 21 for each j, and j = 1, . . . , pe. Therefore, each sequence can
be seen as a vector of length 62 (pe = 62), and each element of the vector is a value
taken from one of 21 (mj = 21 for all j) possible categories.
Any given data set, which in our case can be represented as A1, . . . , An, gives
a distribution of distances on the sample space Ω from a fixed reference position
in Ω. We denote this fixed reference position as S = {s1, . . . , spe}. For a sample
data set, we use n to denote the sample size (n = 1960). Recall the definition of
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Hamming distance given in (2.4), and note that it will take values in 0, 1, 2, . . . , pe.
The algorithm relies on HD vector, which is defined as a (pe + 1)-element vector
H(S) = {H0(S), H1(S), . . . , Hpe(S)}, where
Hq(S) =
n∑
j=1
1(ds(Aj, S) = q), q = 0, . . . , pe.
Thus, Hq(S) counts the number of all sequences of which the Hamming distance to
the given reference position S equal to exactly q (Zhang et al., 2006).
In the categorical sample space Ω, when all the data points have equal probability
to occur at each position, the resulting HD vector is defined as uniform HD vector
(UHD), and denoted by U(Ω) = {U0(Ω), U1(Ω), . . . , Upe(Ω)}. Given an uniformly
distributed data {x1, . . . , xn}, for a reference position S ∈ Ω, the corresponding
uniform HD vector U(S) has pe + 1 elements. The qth element is:
Uq(S) =
n∑
i=1
ds(xi, S), q = 0, . . . , pe,
which is the number of possible sequences with a distance q to the position S (Zhang
et al., 2006). Note that the total number of possible positions in the categorical
sample space is M =
pe∏
j=1
mj, where mj is the number of states for jth attribute.
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Based on Theorem 3 of Zhang et al. (2006), the UHD vector has the following form:
U0(Ω) =
n
M
,
U1(Ω) =
n
M
{(m1 − 1) + (m2 − 1) + · · ·+ (mpe − 1)},
U2(Ω) =
n
M
pe∑
i<j
(mi − 1)(mj − 1),
...
Upe(Ω) =
n
M
(mi − 1)(mj − 1) . . . (mpe − 1).
Note that the UHD vector does not depend on the position S.
The HD vector algorithm sequentially examines the existence of cluster patterns,
and extracts the clusters. At each iteration, the algorithm detects only one cluster
which is defined by a cluster center and a cluster radius. The cluster center is
determined by the position with maximum modified chi-squared statistic based on
HD vector and UHD vector. The cluster radius is defined by the first local minimum
of the frequency distribution of the HD vector. The cluster will be deleted from
the dataset before the next iteration. When there are no more significant clusters
in the remaining data, the iteration stops and the algorithm outputs the number of
clusters. Thus, the algorithm is fully automatic in finding both the clusters and the
number of clusters.
After applying the HD vector algorithm to our data set of sequences, we want to
evaluate the method of dimension reduction based on the distances between clusters.
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Consider two clusters, C1 and C2. Each cluster is made of up of a number of sequences,
say, C1 = {A1, . . . , Aκ1} and C2 = {B1, . . . , Bκ2}. The mean Hamming distance is then
dc(C1, C2) =
∑
i,j
ds(Ai, Bj)
κ1κ2
,
if C1 and C2 are two different clusters. If C1 = C2, then we use
dc(C1, C1) =
∑
i<j
ds(Ai, Aj)
κ1(κ1 − 1)/2 =
∑
i 6=j
ds(Ai, Aj)
κ1(κ1 − 1)
This modification is due to the fact that when comparing the same cluster, all dis-
tances “along the diagonal” will always be zero.
2.2 Results
2.2.1 Cluster evaluation
After the dimensionality reduction, we identified 62 sites of high variability across
the whole HA sequence. The HA protein is composed of two subunits - HA1 and
HA2. The two subunits are linked by disulfide bond and form a protein complex to
exert the full function (Knipe and Howley, 2007). Of the 62 sites, 52 lie within the
HA1 domain. The remaining 10 sites lie within the HA2 domain.
The 1960 viral sequences were partitioned into 23 clusters. Figure 2.1 shows two
dendrograms of the resulting clusters. The top dendrogram is based on the mean
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Hamming distance calculated only for the sites of maximal entropy; whereas in the
bottom dendrogram, the mean Hamming distance is calculated for all sites. The more
variable the corresponding amino acid site, the higher the entropy. The most variable
sites tend to be protein mutation hot spots based on the available sequences. Indeed,
the dendrograms are largely consistent with regard to tree locations. Clusters 1 - 8
are grouped into a clade, while the remaining clusters, with the exception of 21, are
grouped into another clade. Although subtle discrepancies in the specific clade loca-
tion of some clusters exist, the evolution pattern of clades is generally consistent. We
use mean Hamming distance (in amino acids) to measure genetic distance between
two clusters of sequences. If the two clusters are close in mean Hamming distance,
they are considered to be close in lineage evolution history. We regard clusters of
sequences as evolutionary units and infer the genealogy of the clusters by ensemble
of trees, those with small mean Hamming distances will be grouped into a clade (i.e.
in the same trunk of phylogenic tree).
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Figure 2.1: Dendrograms of clusters by mean Hamming distance. This plot is drawn
using hierarchical cluster analysis with complete linkage. The top dendrogram is
based on mean Hamming distance of the 62 sites with highest entropy, and the
bottom one is based on mean Hamming distance of all 566 sites.
2.2.2 Temporal evolution of flu clusters
Figure 2.2 shows the number of sequences in each cluster sorted by the year of
isolation. The clusters that house the vaccine strains are also indicated. The location
order of vaccine strains is consistent with the calendar year according to their strain
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name (and year closeby) e.g. “A/California/7/2004” and “A/Wisconsin/67/2005”,
“A/Victoria/361/2011” and “A/Texas/50/2012” are clustered together. This helps
verify the validity of the clustering results.
Figure 2.2: Histogram of cluster size and vaccine location. The clusters have been
re-ordered in accordance to the sequence of the calendar year.
We can observe from Figure 2.2 that large clusters are generally surrounded by
clusters of much smaller sizes. Thus, the dominant clusters can be identified over
time. We can also observe that a higher number of small clusters are generated
in recent years. This may be due to higher reporting rates, as rapid sequencing
technologies have become increasingly available.
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Figure 2.3: The number of HA protein sequences within each cluster versus the
calendar year of isolation. Each cluster is indicated by a different colour, and the
line width reflects the cluster size.
Each cluster houses strains that exist over one or more influenza seasons. In
Figure 2.3, we plot the number of sequences in each cluster as a function of their
isolation year. The thickness of the line indicates the size of each cluster. We
observe that some clusters have a significantly longer lifespan than others, but no
cluster spans more than seven years. It is also observed that clusters first increase
and then decrease in size over their lifespan. Dominant clusters of viral sequences
replace one another every 2-5 years. However, the occurrence of dominant clusters
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in Figure 2.3 is not periodic within the time span. Once HA evolves away from a
given region of the sequence space, it does not revisit that region at a later time.
This agrees with previous studies of influenza evolution (Plotkin et al., 2002; Knipe
and Howley, 2007).
2.2.3 Evaluation of recommended vaccines
In Table 2.3, we identified dominant clusters and the clusters containing vaccine
strains (vaccine clusters) from 2000 to 2012. Ideally, the vaccine cluster can be the
same as the dominant cluster. Considering the time lag that exists between the
disease outbreak and time of isolation, the vaccine clusters should be as close to the
dominant clusters as possible.
A common observation over all of the years shown indicates that the vaccine
clusters and the dominant clusters are different. For example, from 2000-2004 the
same vaccine strain “A/Moscow/10/99” was used, however, the dominant cluster
changes each year in this time period, moving from a mean distance of 6.15 amino
acids (aa) of the vaccine sequence to 8.37aa, and then 18.68aa in 2002-2004.
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From Table 2.3, we can also see that cluster extinction often coincides with the
existence or introduction of a well-matched vaccine strain. In particular, the extinc-
tion of clusters 6 and 9 coincides with the introduction of vaccines housed in the same
cluster. A similar observation can be made in cluster 11. Ultimate extinction of a
cluster, however, is the result of a combination of various factors, including vaccine
strain and competition between strains. An exploration of strain fitness is a course
for future work.
2.3 Discussion
In this chapter, we have presented a new method for clustering protein sequences
and have applied the method to clustering HA sequences of seasonal influenza A
H3N2. The inclusion of vaccine sequences in the analysis allows us to present im-
portant relationships between the vaccine strains and the dominating flu clusters.
The traditional method for clustering genetic sequences is to use hierarchical ag-
glomerative clustering methods to construct the phylogenetic tree of sequences based
on the pairwise distance of the whole sequence (Plotkin et al., 2002). The number
of resulting clusters are determined by subjective decisions. Our proposed method
is parameter free and doesn’t depend on subjective decisions about the number of
clusters.
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We demonstrate that it is not necessary to perform clustering methods on the
entire HA genome. The 62 sites of the largest entropy can provide similar measures
of Hamming distance. These 62 sites lie within the HA1 and HA2 regions of the
HA genome. Our clustering methodology separates the HA data set into 23 clusters.
Based on the analyses of these clusters, we find that dominant clusters replace one
another every 2-5 years; the dominant clusters are often different from the clusters
housing the vaccine strain, and the extinction of a dominant cluster often coincides
with the existence or introduction of a well-matched vaccine.
Our results are highly consistent with previous studies of HA evolution (Plotkin
et al., 2002; Nelson and Holmes, 2007;  Luksza and La¨ssig, 2014). Plotkin et al.
(2002) found that the persistence of clusters could be used to predict next season’s
influenza sequences. In their analysis, however, some sites of high variability in HA2
are neglected. Their results are not as detailed as ours. Through choosing those
most variable sites of the whole sequence, all the potential evolutionary hot spots
can be taken into account.
Our method can be applied to other components of the influenza virus genome.
The comparisons among studies of other genetic parts of the influenza virus can be
conducted to provide more information for epidemics prediction and vaccine design.
We use the term “dominant” to denote clusters with the greatest number of
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sequences in a given season, but this definition only identifies the cluster containing
the largest number of unique sequences. Therefore, the definition does not account
for (a) the actual number of sequences reported in a season, or (b) their relation to the
frequency of the strain within the population. Although the first issue is relatively
straightforward to fix, the second is more problematic. The influenza sequences
available via IRD are based on voluntary contributions and are therefore not the
result of random sampling. It is thus possible that systematic biases exist in the data
set, including yearly and regional variations ( Luksza and La¨ssig, 2014). Translating
the observed sequences on IRD into an appropriate representation of population-level
frequencies is an important statistical problem which requires careful consideration
in our future work.
Lastly, we point out that our analysis is based on the Hamming distance (2.4),
which means that we regard the sequences close in Hamming distance (in amino
acids) as close in lineage evolution history. This approach is purely mathematical
in that it does not include any potential information on the level of importance
of specific amino acid differences, or their locations. Incorporating such additional
information will improve on the quality of our analysis, and will be included in future
analysis.
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3 Tests for homogeneity of variances applied to
DNA methylation data
As mentioned in Chapter 1, other than differentially methylated marks, differ-
entially variable methylation marks are also relevant to some diseases. However,
many inferences are presented based on the F test or Bartlett’s test. Both tests are
sensitive to the departure of the normality assumption and the presence of outliers.
More than 50 tests have been proposed in the statistical literature to improve the F
test/Bartlett’s test. Conover et al. (1981) compared 56 equal-variance testing pro-
cedures using simulation studies, with the Brown and Forsythe’s test being one of
the top performers. The Brown and Forsythe’s test has larger statistical power than
other tests when samples are from non-normal distributions, while it maintains the
nominal Type I error rate. To our knowledge, the Brown and Forsythe’s test has
not yet been applied to DNA methylation data. Phipson and Oshlack (2014) com-
pared their proposed two equal-variance tests with F test and Bartlett’s test using
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simulated data and evaluated the impact of outliers on the performance of the tests.
However, systematic comparisons among these equal-variance tests are still needed
in order to evaluate their performance for different distributions and the presence
of outliers. In this chapter, we aim to help researchers choose the right test for
equal variances in their DNA methylation data analysis. We compare Phipson and
Oshlack’s equal-variance tests and five commonly used equal-variance tests in the
literature (F test, Bartlett’s test, Levene’s test, trimmed-mean-based Levene’s test,
and Brown-Forsythe test) via systematic simulation studies and real data analysis.
3.1 Methodology
The scientific question we would like to address is to test if the variances of two
populations (e.g., diseased and non-diseased subjects) are the same based on their
corresponding samples. Let Xi and Yi denote the methylation value and the disease
status of subject i, where i = 1, ..., n, with n = n0 +n1, n0 is the number of the non-
diseased subjects (controls, Yi = 0) and n1 is the number of the diseased subjects
(cases, Yi = 1). We would like to test the null hypothesis H0 : σ
2
0 = σ
2
1 versus
the alternative hypothesis Ha : σ
2
0 6= σ21, where σ20 and σ21 are the variances of the
non-diseased subjects and diseased subjects, respectively.
Next, we would like to compare the performance of the seven equal-variance tests:
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F test, Bartlett’s test, Levene’s test, trimmed-mean-based Levene’s test, Brown and
Forsythe’s test, Phipson and Oshlack’s equal variance test based on absolute differ-
ence, and Phipson and Oshlack’s equal variance test based on squared difference. We
denoted the seven tests by F , Bartlett, Levene, L.trim, BF, PO.AD, and PO.SQ,
respectively.
The F test is to test homogeneity of variance for a two-sample problem based on
the ratio of variances. To test homogeneity of variance in multiple-sample situation,
one popular test is Bartlett’s test (Bartlett, 1937; Shoemaker, 2003). The Levene,
L.trim, BF, PO.AD, and PO.SQ tests employ the ideas of equal-mean tests (e.g.,
t-test or one-way ANOVA) and replace the original data xki in the test statistics by
the transformed data zki = |xki − c| or zki = (xki − c)2, where the subscription k
indicates the group, i indicates the subject within the group, and c is a measure of
central tendency, such as within-group mean or overall mean.
Specifically, Levene, L.trim, and BF tests replace xki by zki in one-way ANOVA’s
F test statistic; PO.AD and PO.SQ tests replace xki by zki in the moderated t-test
statistic (Smyth, 2004). The definitions of these seven equal-variance tests are given
as follows.
Phipson and Oshlack (2014) proposed two equal-variance tests based on the fol-
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lowing two linear regression models:
z∗i =β0 + β1yi + i,
z∗∗i =γ0 + γ1yi + ξi,
i =1, . . . , n0 + n1,
(3.1)
where
z∗i =c
∗
i |xi − g(xi)|,
z∗∗i =c
∗
i [xi − g(xi)]2,
and g(xi) =
1
n0
n∑
i=1
xiI(yi = 0) for controls or g(xi) =
1
n1
n∑
i=1
xiI(yi = 1) for cases.
The value of c∗i is
c∗i =

√
n0
n0−1 if yi = 0 (i.e., controls),√
n1
n1−1 if yi = 1 (i.e., cases),
In matrix terminology, the two linear models can be written as:
E(z∗) =Ydβ,
E(z∗∗) =Ydγ,
(3.2)
where
Yd =
 1, y1..., ...
1, yn
 , β = ( β0
β1
)
, γ =
(
γ0
γ1
)
.
And the regression coefficients can be estimated as
βˆ = (Y Td Yd)
−1Y Td z
∗,
γˆ = (Y Td Yd)
−1Y Td z
∗∗,
(3.3)
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Phipson and Oshlack (2014) mentioned that testing for equal-variance between
cases and controls is equivalent to testing if the slope β1 (or γ1) is equal to zero.
Phipson and Oshlack (2014) applied moderated t-test (Smyth, 2004) to borrow in-
formation across CpG sites to improve the test of the null hypothesis H0 : β1 = 0
(or γ1 = 0) for a given CpG site. The moderated t-test statistics is defined as:
t˜ =
βˆ1
s˜
√
ν
, (3.4)
where ν is the diagonal element from the positive definite matrix (Y Td Yd)
−1 and s˜
is the standard deviation of the squeezed variance calculated according to Smyth’s
(2004) procedures.
The F test statistic is asymptotically F distributed under the null hypothesis:
F =
S21
S20
d→ Fn1−1,n0−1,
where
S2k =
1
(nk − 1)
nk∑
i=1
(xki − x¯k)2,
x¯k =
1
nk
nk∑
i=1
xki,
k = 0, 1, n0 and n1 are the sample sizes for controls and cases, respectively, and
N = n0 + n1.
For two-sample comparison (K = 2), Bartlett’s test statistic is
X2 =
(n1 + n0 − 2) log(S2p)−
∑2
k=1 (nk − 1) log (S2k)
1 + 1
3
(∑2
k=1
(
1
(nk−1)
)
− 1
(n1+n0−2)
) d→ χ21,
36
where
S2p =
1
(N − 2)
2∑
k=1
(nk − 1)S2k .
The numerator of the Bartlett’s test for two-sample comparison of variances is
numer = (n1 + n0 − 2) log
(
S2p
)− [(n1 − 1) log (S21)+ (n0 − 1) log (S20)]
= log

[
(Sp)
2
]n1+n0−2
[
(S1)
2
]n1−1 [
(S0)
2
]n0−1

= log

[
(Sp)
2
(S1)
2
]n1−1 [
(Sp)
2
(S0)
2
]n0−1
= log
{[
1
(n1 + n0 − 2)
[
(n1 − 1) + (n0 − 1) S
2
0
S21
]]n1−1 [ 1
(n1 + n0 − 2)
[
(n0 − 1) + (n1 − 1) S
2
1
S20
]]n0−1}
= log
{[
1
(n1 + n0 − 2)
[
(n1 − 1) + (n0 − 1) 1
F
]]n1−1 [ 1
(n1 + n0 − 2)
[(n0 − 1) + (n1 − 1)F ]
]n0−1}
,
where
S21
S20
is the F test statistic.
Hence, Bartlett’s test for two-sample comparison of variances is similar to F test,
but they have small differences in performance when applied to data with a small
sample size due to different derived asymptotic distributions.
Levene’s test statistic for two-sample comparison of variances is defined as
W =
(n− 2)[n1(w¯1 − w¯)2 + n0(w¯0 − w¯)2]∑n1
i=1(w1i − w¯1)2 +
∑n0
j=1(w0j − w¯0)2
,
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where
w1i =|x1i − x¯1|, x¯1 = 1
n1
n1∑
i=1
x1i,
w0j =|x0j − x¯0|, x¯0 = 1
n0
n0∑
j=1
x0i,
w¯1 =
1
n1
n1∑
i=1
w1i,
w¯0 =
1
n0
n0∑
j=1
w1j,
w¯ =
1
n
[
n1∑
i=1
w1i +
n0∑
j=1
w0j
]
.
Trimmed-mean-based Levene’s test for two-sample comparison of variances has
the same format as Levene’s test. The only difference is in the definition of w1i and
w0j:
w1i =|x1i − xˇ1|,
w0j =|x0j − xˇ0|,
where xˇ1 and xˇ0 are within-group 10% trimmed means for cases and controls, re-
spectively.
Brown-Forsythe test statistic uses the same format as Levene’s test for two-sample
comparison of variances. The only difference is in the definition of w1i and w0j:
w1i =|x1i − x˜1|,
w0j =|x0j − x˜1|,
where x˜1 and x˜0 are medians for cases and controls, respectively.
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3.2 Simulation studies
3.2.1 Simulation setting
We conducted two simulation studies. Each study contains several scenarios and
only evaluates the balanced samples. For each scenario, we generated 100 simulated
data sets. For each simulated data set, we generated DNA methylation levels for
1000 CpG sites. For each CpG site, we tested if the DNA methylation levels are
differentially variable between non-diseased and diseased subjects using each of the
seven equal-variance tests. A test is claimed as significant if its p-value is < 0.05.
Two-sided tests were used by the R statistical software (R Core Team, 2008) for the
simulation studies.
In Simulation Study I, we evaluated the performance of the seven tests by the
following aspects: (1) the violation of the normality assumption, (2) the presence of
heterogeneity of means, (3) the existence of outliers, (4) various sample sizes. We
employed three parametric distributions to generate the methylation data: normal
distribution, t distribution, and chi-squared distribution. To evaluate the impact of
different group means on these tests, we considered two scenarios: equal group means
(eqM) and different group means (diffM). To evaluate the influence of outliers, we
randomly picked a diseased subject and replaced its DNA methylation value by the
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maximum DNA methylation level of all CpG sites. We also used three sample sizes:
20 (small), 50 (median), and 200 (large), to evaluate the effect of sample size on the
performance.
The distribution settings for the scenarios in Simulation Study I are summarized
in Table 3.1. Simulation study I had 3 (distributions) × 2 (scenarios of group means)
× 2 (with or without outlier) × 3 (sample sizes) = 36 different comparisons.
Table 3.1: The distribution settings for the scenarios in Simulation Study I.
Mean & Variance Normal t distribution chi-squared distribution
(mean, var) Non-D D Non-D D Non-D D
eqM & eqV N(0, 1) N(0, 1) t10 (0, 1.25) t10 (0, 1.25) χ22 (2,4) χ
2
2 (2,4)
eqM & diffV N(0, 1) N(0, 2) t10 (0, 1.25) t10/3 (0, 2.5) χ
2
2 (2,4) χ
2
0.5,1.5 (2,7)
diffM & eqV N(0, 1) N(1.5, 1) t10 (0, 1.25) t15,1.489 (1.57, 1.25) χ22 (2,4) χ
2
1,0.5 (1.5,4)
diffM & diffV N(0, 1) N(1.5, 2) t10 (0, 1.25) t6,2.393 (2.75, 2.5) χ22 (2,4) χ
2
4 (4,8)
eqM: equal-mean; eqV: equal-variance; diffM: different-mean; diffV:different-variance; D:
diseased; Non-D: non-diseased; N(a, b): normal distribution with mean a and variance b;
tc: t-distribution with degrees of freedom c; td,e: non-central t-distribution with degrees
of freedom d and non-centrality parameter e; χ2f : chi-squared distribution with degrees
of freedom f ; χ2g,h: non-central chi-squared distribution with degrees of freedom g and
non-centrality parameter h.
In Simulation Study II, we considered two Bayesian hierarchical models. First,
we generated the DNA methylation values from a normal distribution with the vari-
ance sampled from an inverse chi-squared distribution (denoted as c.N). Second, we
generated the DNA methylation values from a chi-squared distribution, the degrees
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of freedom of which were generated from the scaled inverse chi-squared distribution
scale-inv-χ2(d0, s
2
0) (denoted as c.chisq). To evaluate the type I error rate (equal-
variance scenario), we set the degrees of freedom d0 = 20 and the scaling factor
s20 = 0.64 for both non-diseased and diseased subjects. To evaluate the power of
the tests (different-variance scenario), we set the scaling factor as s20 = 0.64 for non-
diseased subjects and s20 = 1.5 for diseased subjects. The degrees of freedom are set
to be d0 = 20 for both non-diseased and diseased subjects. To evaluate the effect of
outliers and sample size, we used the same procedures in Simulation Study I. Thus,
Simulation Study II had 2 (distributions) × 2 (with or without outlier) × 3 (sample
sizes) = 12 different comparisons.
For each simulated data set, we assessed the performance of an equal-variance
test by the estimated type I error rate and power. The estimated type I error rate
is the proportion of significant tests detected by the equal-variance test among the
1000 CpG sites in a simulated data set generated from the null hypothesis (i.e., CpG
sites are non-differentially variable). Estimated power is the proportion of significant
tests detected by the equal-variance test among the 1000 CpG sites in a simulated
data set generated from the alternative hypothesis (i.e., CpG sites are differentially
variable).
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3.2.2 Simulation results
Figure 3.1 and Table 3.2 summarize the observed results from all the scenarios:
(1) F test, Bartlett’s test, Levene’s test, and PO.AD test have type I error rates
higher than the nominal value (0.05) in most scenarios, while L.trim, BF, and PO.SQ
maintain the nominal type I error rates for almost all scenarios; (2) BF test and
PO.SQ test perform better than the other tests in terms of having high power while
maintaining the nominal type I error rate; (3) F test and Bartlett’s test have very
similar performance and perform best under normality assumption, while both of
them have type I error rates higher than the nominal value (0.05) when the normality
assumption is violated; (4) PO.AD test tends to have a type I error rate higher than
the nominal value of 0.05 for a majority of simulation scenarios, while PO.SQ test
can maintain the nominal type I error rate of 0.05 for almost all simulation scenarios;
(5) For almost all of the scenarios where PO.AD test maintains the nominal type I
error rate, PO.AD test has the largest power, while the PO.SQ test is less powerful
than other tests in the similar situation of PO.AD; and (6) the power has improved
a lot by increasing the sample size from 20/50 subjects per group to 200 subjects
per group. In addition, we observe that the ranks of the seven tests do not change
much as the sample size increases. The ranks of power by different sample sizes are
presented in Appendix A.
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Figure 3.1: Plots of nreject versus m, where nreject is the number of scenarios where
the test has inflated type I error rate and m is the median of the ranks of power. For
ranks with ties, average ranks are used. The upper-right, bottom-left, and bottom-
right panels are based on scenarios with sample size 200, 50, and 20 subjects per
group, respectively. The upper-left panel is based on all 48 scenarios.
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Table 3.2: The summary of the simulated 48 comparisons for the seven tests.
n Distribution F Bartlett Levene L.trim BF PO.AD PO.SQ
200 N(incl. c.N) 2(3) 2(3) 5(3) 3.25(0) 3.25(0) 4.75(2) 2(1)
200 t -(4) -(4) 2(2) 3(1) 4(1) 2(2) 2(0)
200 chisq (incl. c.chisq) -(6) -(6) -(6) 1(3) 1.5(1) -(6) 2.5(0)
50 N(incl. c.N) 1.5(3) 1.5(3) 2(5) 4(1) 4.5(0) 1(4) 3(1)
50 t -(4) -(4) 2(3) 1(0) 2(0) 1(3) 3(0)
50 chisq (incl. c.chisq) -(6) -(6) -(6) 1(3) 2(1) -(6) 2.5(0)
20 N(incl. c.N) 1.5(3) 1.5(3) -(6) 4(1) 4(0) 1(4) 3(1)
20 t -(4) -(4) 2(3) 1.5(0) 2.5(0) 1(2) 3.5(0)
20 chisq (incl. c.chisq) -(6) -(6) -(6) 1(3) 2(1) -(6) 3(2)
Total 1.5(39) 1.5(39) 2(40) 2(12) 2(4) 1(35) 3(5)
N : Normal distribution;
c.N : Bayesian hierarchical model with normal distribution;
t : t distribution;
chisq : Chi-squared distribution;
c.chisq : Bayesian hierarchical model with chi-squared distribution;
m(nreject) : m denotes the median of the ranks of the power, nreject denotes the number of the
scenarios where the test has inflated type I error rate;
“-” : no power can be considered because the test has inflated type I error rates for all the scenarios
in the situation.
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3.3 Real data analysis
3.3.1 Data description
To evaluate the performance of the seven equal-variance tests for real data sets,
we used two data sets (GSE37020 and GSE20080) downloaded from the public repos-
itory: Gene Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/geo). Both data sets
contain DNA methylation (DNAm) profiles of 27,578 CpG sites measured from liq-
uid based cytology (LBC) cervical smear samples by IlluminaHumanMethylation27
platform.
GSE37020 contains a total of 48 samples, 24 of which have normal histology and
the remaining 24 are cervical intraepithelial neoplasia of grade 2 or higher (CIN2+).
All of them are human papillomavirus (HPV) positive. Normal and CIN2+ samples
are age-matched. GSE20080 also contains 48 samples. A total of 30 samples (11 HPV
positive samples and 19 HPV negative samples) have normal cytology. The other 18
samples (all HPV positive) are with CIN2+. Moreover, normal and CIN2+ samples
were age-matched. After the procedures of quality control and data preprocessing,
the remaining 22,859 are matched CpG sites in both data sets. We used these 22,859
CpG sites in our real data analysis. The procedures and results of quality control
(QC) and data preprocessing are presented in Appendix B.
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We used GSE37020 as the discovery set to detect CpG sites differentially vari-
able between normal cytology samples and CIN2+ samples. To control for multiple
comparisons, we applied the Benjamini and Hochberg’s method to adjust p-values
so that the false discovery rate (FDR) is controlled at the level of 0.05. Specifically,
a CpG site was claimed significant if its FDR-adjusted p-value was < 0.05. We
then validated these differentially variable CpG sites by using the GSE20080 data
set. If an equal-variance test for a given CpG site had FDR-adjusted p-value < 0.05
in the analysis of GSE37020 and had un-adjusted p-value < 0.05 in the analysis
of GSE20080, we then claimed that the significance of the test in GSE37020 was
validated in GSE20080.
3.3.2 Results
For the real data set GSE37020, the numbers of significant CpG sites (i.e., CpG
sites with FDR-adjusted p-value < 0.05) obtained by the seven equal-variance tests
are 2318 (F), 2315 (Bartlett), 235 (Levene), 15 (L.trim), 7 (BF), 130 (PO.AD), and
0 (PO.SQ), respectively. The numbers of significant CpG sites detected by F test
and Bartlett test are much larger than those detected by other tests. No significant
CpG sites were detected by the PO.SQ test.
The numbers/proportions of significant CpG sites validated by GSE20080 are
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1154/49.8% (F), 1164/50.3% (Bartlett), 183/77.9% (Levene), 9/60.0% (L.trim), 3/42.9%
(BF), and 91/70% (PO.AD), respectively (see Table 3.3). The six tests (except
PO.SQ) have large proportions of significant CpG sites validated by the testing set
GSE20080. Overall, the robust equal-variance tests have a larger proportion of vali-
dated significant CpG sites than F or Bartlett test.
Since the F test and Bartletts test are sensitive to outliers, we check the num-
ber/proportion of significant CpG sites containing outliers detected based on GSE37020.
The numbers/proportions are 1503/64.8% (F), 1501/64.8% (Bartlett), 70/29.8%
(Levene), 2/13.3% (L.trim), 2/28.6% (BF), and 64/49.2% (PO.AD), respectively
(see the second column of Table 3.3). For the F test and Bartletts test, more than
60% significant CpG sites contain outliers. For robust tests (e.g., Levene, L.trim,
and BF), the proportions are relatively small (< 30%).
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Table 3.3: The performance of seven equal-variance tests based
on data sets GSE37020 and GSE20080.
Test
GSE37020 GSE20080
pValid
nSig(p.adj < 0.05) nValid(pval < 0.05)
F 2318 1154 49.8%
Bartlett 2315 1164 50.3%
Levene 235 183 77.9%
L.trim 15 9 60.0%
BF 7 3 42.9%
PO.AD 130 91 70%
PO.SQ 0 0 -
nSig : the number of significant CpG sites detected in GSE37020 based
on FDR-adjusted p-value < 0.05;
nValid : the number of validated CpG sites in GSE20080 based on un-
adjusted p-value < 0.05;
pTV : = nV alidnSig , the proportion of significant CpG sites detected in
GSE37020 and validated in GSE20080;
We then checked if the significant CpG sites containing outliers in GSE37020
would still contain outliers in GSE20080. The number/proportion of such CpG sites
are 495/32.9% (F), 497/33.1% (Bartlett), 34/48.6% (Levene), 0/0% (L.trim), 0/0%
(BF), and 31/48.4% (PO.AD), respectively (see third column of Table 3.3).
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Table 3.4: The number (proportion) of significant CpG sites
that contain outliers in GSE37020 and GSE20080.
Test
GSE37020 GSE20080
nOut.Sig (pOut.Sig) nOut.Valid (pOut.Valid)
F 1503 (64.8%) 495 (32.9%)
Bartlett 1501 (64.8%) 497 (33.1%)
Levene 70 (29.8%) 34 (48.6%)
L.trim 2 (13.3%) 0 (0%)
BF 2 (28.6%) 0 (0%)
PO.AD 64 (49.2%) 31 (48.4%)
PO.SQ 0 (-) 0 (-)
nOut.Sig (pOut.Sig) : the number (proportion) of significant CpG sites
containing outliers detected in GSE37020;
nOut.Valid (pOut.Valid) : the number (proportion) of the significant CpG
sites with outliers that also contain outliers in GSE20080.
We next checked the parallel boxplots of DNA methylation level versus case-
control status for the top CpG site (i.e., having the smallest p-value for testing
equal variance) obtained by each of the seven tests based on GSE37020. The top
CpG sites detected by the seven equal-variance tests are cg26363196 (F, Bartlett,
PO.AD), cg00027083 (Levene and L.trim), and cg06675478 (BF), respectively. All
these top CpG sites were validated in GSE20080. Figure 3.2 shows the boxplots
of these three unique top CpG sites. We found that all these three top CpG sites
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contain at least one outlier in either GSE37020 or GSE20080.
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Figure 3.2: Parallel boxplots of DNA methylation level versus case-control status for
the obtained three unique top CpG sites.
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3.4 Discussion
Recently, Phipson and Oshlack (2014) proposed two new tests for homogeneity
of variances for DNA methylation data analysis. However, the performance of their
methods has not been compared with existing tests that are robust against the
violation of the normality assumption, such as Levene’s test, trimmed-mean-based
Levene’s test, and Brown Forsythe’s test.
In this chapter, we systematically compare the performance of the two new equal-
variance tests with the F test, Bartlett’s test, Levene’s test, trimmed-mean-based
Levene’s test, and Brown Forsythe’s test via two sets of simulation studies and one
real-data analysis. Based on the simulation results, BF, L.trim, and PO.SQ tests for
equality of variance have relatively high power while keeping the nominal type I error
rate for most of the simulation scenarios. Levene’s test has type I error rates higher
than the nominal value 0.05 for a majority of the scenarios, even for the scenarios
where data are generated from a normal distribution. All the seven equal-variance
tests have low power when data are generated from chi-squared distributions. Com-
pared to real DNA methylation data, our simulation studies do not cover all scenarios
encountered in real DNA methylation data analysis. However, our simulation studies
provide useful information about the performance of the seven equal-variance tests.
Our simulation studies and real data analysis confirm the fact that F/Bartlett’s
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test are very sensitive to the violation of the normality assumption and the pres-
ence of outliers. However, outliers might be biologically important as pointed out
by Teschendorff and Widschwendter. The real data analysis in this chapter also
shows that a number (30% - 50%) of significant CpG sites with outliers detected
in GSE37020 also contain outliers in GSE20080. Our real data analysis also agrees
with Teschendorff and Widschwendter’s observation that changes in DNA methyla-
tion for differentially variable CpG sites are heterogeneous and stochastic as shown
in the parallel boxplots for CpG cg26363196 in Figure 3.2. We notice in the real data
analyses that some outliers might be artifacts. For example, more than 60% of the
1503 significant CpG sites containing outliers do not contain outliers in GSE20080.
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4 Robust joint score tests for DNA methylation
data analysis
Since both mean and variance are biologically meaningful in DNA methylation
analysis, it is more efficient to test for equal means and equal variances simultane-
ously. The joint likelihood ratio test (jointLRT) and the two-sample Kolmogorov-
Smirnov (KS) test are two traditional methods for this task. Ahn and Wang (2013)
proposed a joint score test (AW), which is a quadratic form of a vector of two tests.
One of them is to test for equal means, and the other is to test for equal variances.
However, they did not provide the derivation of the asymptotic distribution for this
test nor the comparison of AW with jointLRT or KS that are the benchmark tests
in the statistical literature.
In this chapter, we derive the asymptotic distribution of the AW joint test statis-
tic and make comprehensive comparisons between AW, jointLRT, and KS tests.
Although a normal distribution is usually assumed for methylation data, the viola-
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tion of the normality assumption and the presence of outlying points can often be
observed in the analysis of real data. Bi-modal distributions are also encountered
frequently in practice. To improve on the robustness of the AW joint test, we propose
three tests based on absolute deviation from mean (iAW.Lev), median (iAW.BF),
and trimmed mean (iAW.TM), respectively.
4.1 Methodology
4.1.1 Asymptotic distribution of AW-type joint test statistics
Let Xi and Yi denote the methylation value and the disease status of subject i,
where i = 1, . . . , n, with n = n0 + n1, n0 being the number of non-diseased subjects
(controls, Yi = 0) and n1 being the number of diseased subjects (cases, Yi = 1).
To detect methylation loci that are relevant to the disease based on means and
variances, the corresponding hypothesis is considered as H0 : µ0 = µ1 and σ
2
0 = σ
2
1
versus H1 : µ0 6= µ1 or σ20 6= σ21, in which µ0 and µ1 are means of methylation levels
for controls and cases, respectively, and σ20 and σ
2
1 are the corresponding variances.
Instead of directly testing the above hypothesis, Ahn and Wang (2013) proposed
to test H ′0 : β1 = β2 = 0 versus H
′
a : β1 6= 0 or β2 6= 0, where β1 and β2 are the
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regression coefficients of the following logistic regression:
logit[Pr(Yi = 1|xi, zi)] = β0 + β1xi + β2zi + εi, (4.1)
and zi is the within-group squared deviation for subject i, which is defined as
zi =

(xi − x¯1)2, if Yi = 1
(xi − x¯0)2, if Yi = 0,
(4.2)
and x¯1 =
∑n
i=1
xiI[Yi=1]
n1
and x¯0 =
∑n
i=1
xiI[Yi=0]
n0
are the sample means for cases and
controls.
The log-likelihood function of the logistic regression (4.1) is
l(θ) =
n∑
i=1
Yi(β0 + β1xi + β2zi)− log[1 + exp(β0 + β1xi + β2zi)],
where θ = (β0, β1, β2)
T . The score statistics are partial derivatives of the log-
likelihood function with respect to the parameters of interest, evaluated at the values
postulated by the null hypothesis H ′0 : β1 = β2 = 0.
We have
∂l(θ)
∂β0
=
n∑
i=1
(Yi − pii),
∂l(θ)
∂β1
=
n∑
i=1
xi(Yi − pii),
∂l(θ)
∂β2
=
n∑
i=1
zi(Yi − pii),
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where
pii = Pr(Yi = 1|xi, zi) = exp(β0 + β1xi + β2zi)
1 + exp(β0 + β1xi + β2zi)
.
Under H ′0 : β1 = β2 = 0,
pii =
exp(β0)
1 + exp(β0)
= pi0.
Let ∂l(θ)
∂β0
= 0 under H ′0. The maximum likelihood estimate of pi0 is:
pˆi0 = Y¯ =
n∑
i=1
Yi
n
.
Hence, the score statistics are
U1 =
∂l(θ)
∂β1
∣∣∣∣
pˆi0=Y¯ ,β1=β2=0
=
n∑
i=1
xi(Yi − Y¯ ),
U2 =
∂l(θ)
∂β2
∣∣∣∣
pˆi0=Y¯ ,β1=β2=0
=
n∑
i=1
zi(Yi − Y¯ ).
Under H ′0, let U = (U1, U2)
T and Σ0 = Cov(U) denote the vector of the score
statistics and the covariance matrix of U, respectively. Based on Fahrmeir (1987)
and Dobson (1990, Page 51),
U
d→ N(0,Σ0),
and
Σ
−1/2
0 U
d→ N(0, I2),
where I2 is a 2× 2 identity matrix. Therefore,
(Σ
−1/2
0 U)
T (Σ
−1/2
0 U) = U
TΣ−10 U
d→ χ22. (4.3)
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The AW test statistic T = UT Σˆ−1U is a quadratic form of the vector of the score
statistics, where Σˆ is the estimate of the covariance matrix Σ0 under H
′
0.
Proposition 4.1.1 Under H ′0 : β1 = β2 = 0, the estimated covariance matrix Σˆ has
the following analytical form:
Σ̂ = ny¯(1− y¯)
(
σˆ2x σˆxz
σˆxz σˆ
2
z
)
, (4.4)
where σˆ2x =
∑n
i=1
(xi−x¯)2
n
and σˆ2z =
∑n
i=1
(zi−z¯)2
n
are the sample variances for xi and
zi, and σˆxz =
∑n
i=1
(xi−x¯)(zi−z¯)
n
is the sample covariance between xi and zi, and y¯ is
the realization of Y¯ . The asymptotic distribution of T = UT Σˆ−1U is a chi-squared
distribution with two degrees of freedom.
Proof. Note that in logistic regression, Yi are random variables, while xi and zi
are fixed (i.e., non-random). We can get
E (U1) =
n∑
i=1
xiE (Yi − Y¯ ) = 0,
E (U2) =
n∑
i=1
ziE (Yi − Y¯ ) = 0.
Hence, we have
Σ0 =Cov (U)
=E
(
UUT
)− [E (U)] [E (U)]T
=E
(
UUT
)
.
(4.5)
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Define J = (1)n×n, I is a n×n identity matrix, X =
 x1 z1... ...
xn zn
, Y =
 Y1...
Yn
,
then X¯ = 1
n
JX, U =

n∑
i=1
xi(Yi − Y¯ )
n∑
i=1
zi(Yi − Y¯ )
 = XT (I− 1nJ)Y.
E
(
UUT
)
=E
[
XT
(
I− 1
n
J
)
YYT
(
I− 1
n
J
)
X
]
=E
[
(X− X¯)TYYT (X− X¯)]
=(X− X¯)TE (YYT )(X− X¯).
We have
YYT =
 Y1...
Yn
( Y1, · · · , Yn )
=
 Y
2
1 Y1Y2 . . . Y1Yn
...
...
. . .
...
YnY1 YnY2 . . . Y
2
n
 .
Note that Y 2i = Yi and E (Yi) = pii. We have
E (YYT ) =E
 Y
2
1 Y1Y2 . . . Y1Yn
...
...
. . .
...
YnY1 YnY2 . . . Y
2
n

=E
 Y1 Y1Y2 . . . Y1Yn... ... . . . ...
YnY1 YnY2 . . . Yn

=
 pi1 pi1pi2 . . . pi1pin... ... . . . ...
pinpi1 pinpi2 . . . pin
 .
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Under H ′0 : β1 = β2 = 0, pii = pi0. Therefore, we have
E (YYT ) =
 pi0 pi
2
0 . . . pi
2
0
...
...
. . .
...
pi20 pi
2
0 . . . pi0

=pi20J + pi0(1− pi0)I.
Hence,
E
(
UUT
)
=(X− X¯)T (pi20J + pi0(1− pi0)I)(X− X¯)
=(X− X¯)Tpi20J(X− X¯) + (X− X¯)Tpi0(1− pi0)I(X− X¯)
=pi20(X− X¯)TJ(X− X¯) + pi0(1− pi0)(X− X¯)T I(X− X¯).
Since (X− X¯)TJ(X− X¯) = (0)2×2, we have
E
(
UUT
)
=pi0(1− pi0)(X− X¯)T I(X− X¯)
=pi0(1− pi0)(X− X¯)T (X− X¯)
=pi0(1− pi0)

n∑
i=1
(xi − x¯)2
n∑
i=1
(xi − x¯)(zi − z¯)
n∑
i=1
(xi − x¯)(zi − z¯)
n∑
i=1
(zi − z¯)2
 .
Under H ′0 : β1 = β2, we can estimate pi0 by the realization of Y¯ , y¯ =
n1
n
. Thereby,
we have
Σˆ =y¯(1− y¯)
( ∑n
i=1(xi − x¯)2
∑n
i=1(xi − x¯)(zi − z¯)∑n
i=1(xi − x¯)(zi − z¯)
∑n
j=1(zj − z¯)2
)
=ny¯(1− y¯)
(
σˆ2x σˆxz
σˆxz σˆ
2
z
)
,
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where σˆ2x =
n∑
i=1
(xi − x¯)2
n
, and σˆ2z =
n∑
i=1
(zi − z¯)2
n
are the sample variances for xi and
zi, and σˆxz =
n∑
i=1
(xi − x¯)(zi − z¯)
n
is the sample covariance between xi and zi. Based
on formula (4.3), by Slutsky’s theorem,
T = UT Σˆ−1U d→ χ22. (4.6)

4.1.2 Three improved joint score tests
To improve on the robustness of the deviation in (4.2), we propose three improved
joint score tests. In the first improved joint score test (denoted as iAW.Lev), we re-
place the within-group squared deviation by within-group absolute deviation Levene
(1960):
zLi =

|xi − x¯1|, if Yi = 1;
|xi − x¯0|, if Yi = 0.
(4.7)
For the logistic regression logit(Pr(Yi = 1)|xi, zLi ) = βL0 + βL1 xi + βL1 zLi , under the
null hypothesis H∗0 : β
L
1 = β
L
2 = 0, the joint score test statistic T
Lev is asymptotically
chi-squared distributed with two degrees of freedom:
TLev = (ULev)T (ΣˆLev)−1ULev d→ χ22,
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where ULev =
(
U1, U
L
2
)T
, UL2 =
∑n
i=1 z
L
i (yi − y¯),
ΣˆLev = ny¯ (1− y¯)
(
σˆ2x σˆxzL
σˆxzL σˆ
2
zL
)
,
σˆ2zL is the sample variance for z
L
i , and σˆxzL is the sample covariance between xi
and zLi . Note that the proposed improved joint test is different from Levene’s test
(Levene, 1960) in that Levene’s test regards zLi as random and uses ANOVA, while
the proposed improved joint test regards zLi as fixed (i.e., non-random) and uses a
logistic regression framework.
In the second improved joint score test, we replace the sample means in the TLev
by sample medians Brown and Forsythe (1974):
zBFi =

|xi − x˜1|, if Yi = 1;
|xi − x˜0|, if Yi = 0,
(4.8)
where x˜1 and x˜0 are the sample medians for cases and controls, respectively. Under
the null hypothesis HBF0 : β
BF
0 = β
BF
1 = 0, the joint score test statistic T
BF follows
asymptotically the chi-squared distribution with two degrees of freedom:
TBF = (UBF )T (ΣˆBF )−1UBF d→ χ22,
where UBF =
(
U1, U
BF
2
)T
, UBF2 =
∑n
i=1 z
BF
i (yi − y¯),
ΣˆBF = ny¯ (1− y¯)
(
σˆ2x σˆxzBF
σˆxzBF σˆ
2
zBF
)
,
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σˆ2zBF is the sample variance for z
BF
i , and σˆxzBF is the sample covariance between xi
and zBFi .
In the third improved joint score test, we replace the sample means in the TLev
by trimmed sample means Brown and Forsythe (1974):
zTMi =

|xi − xˇ1|, if Yi = 1;
|xi − xˇ0|, if Yi = 0,
(4.9)
where xˇ1 and xˇ0 are the 25% trimmed sample means for cases and controls, respec-
tively. The 25% trimmed mean for a sample is the sample mean after 25% from both
the lowest and highest values are trimmed.
For the logistic regression model logit(Pr(Yi = 1)|xi, zTMi ) = βTM0 + βTM1 xi +
βTM1 z
TM
i , under the null hypothesis H
TM
0 : β
TM
1 = β
TM
2 = 0, the joint score test
statistic T TM is asymptotically chi-squared distributed with two degrees of freedom:
T TM = (UTM)T (ΣˆTM)−1UTM d→ χ22,
where UTM =
(
U1, U
TM
2
)T
, UTM2 =
∑n
i=1 z
TM
i (yi − y¯),
ΣˆTM = ny¯ (1− y¯)
(
σˆ2x σˆxzTM
σˆxzTM σˆ
2
zTM
)
,
σˆ2zTM is the sample variance for z
TM
i , and σˆxzTM is the sample covariance between xi
and zTMi .
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4.2 Simulation studies
4.2.1 Simulation setting
We conducted comprehensive simulations to compare the performance of the three
improved tests with the three existing methods: the joint likelihood ratio test based
on the normal distribution (jointLRT) (Pearson and Neyman, 1930; Wilks, 1938), the
Kolmogorov-Smirnov test (KS) (William, 1971), and AW test. Zhang et al. (2012)
attained the mathematical expression and the exact distribution of jointLRT test
statistics under normal distribution. Due to computational complexity, we used the
asymptotic distribution of jointLRT in our simulation studies.
The simulation studies examined the following four aspects and their impacts
on these six tests: (1) various sample sizes, (2) the presence of heterogeneity of
means and variances, (3) the violation of the normality assumption, and (4) out-
liers. We considered various sample sizes: (n0, n1)=(100, 100), (n0, n1)=(50, 50), and
(n0, n1)=(20, 20). Four parametric models were employed to generate the methyla-
tion data: the normal distribution, the Beta distribution, the chi-square distribution,
and the mixture of two normal distributions. To evaluate the impact of outliers,
we replaced the DNA methylation level of one randomly picked disease subject by
max{x1,max, (Q3 + 3(Q3 −Q1))}, where x1,max denotes the maximum DNA methy-
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lation level of the diseased samples, and Q1 and Q3 are the first and third quartiles,
respectively.
We computed the empirical Type I error rates and the power of the six tests
under different scenarios: (1) Type I error scenario (eqM & eqV): distributions of
non-diseased and diseased samples are the same; (2) Power scenario I (diffM & eqV):
distributions of non-diseased and diseased samples are different in means only; (3)
Power scenario II (eqM & diffV): distributions of non-diseased and diseased samples
are different in variances only; and (4) Power scenario III (diffM & diffV): distribu-
tions of non-diseased and diseased samples are different in both means and variances.
We conducted 10, 000 repetitions to estimate Type I error rates under scenario (1).
For the simulated power, the results were based on 5,000 repetitions. We used the
critical values of the observed test statistics under the null to determine the simulated
power in order to make the power comparison fair.
4.2.2 Simulation results
Overall, the three improved joint score tests performed better than the other three
methods when methylation levels contained outliers and had different variances be-
tween diseased and non-diseased samples. Furthermore, iAW.BF is the most robust
in terms of power among all the scenarios. The KS test had conservative empirical
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Type I error rates and the lowest power in many scenarios.
Table 4.1: The type I error (×100) and power (×100) for the six tests evaluated at
5%, 1%, and 0.5% significance levels when methylation β-values were generated from
the normal distribution without or with an outlier. The numbers of non-diseased and
diseased samples are (100, 100).
Scenarios Out Level(%) jointLRT KS AW iAW.Lev iAW.BF iAW.TM
eqM&eqV No 5 4.9 3.5 5.0 5.0 5.2 5.4
No 1 0.9 0.5 0.8 1.0 1.0 1.2
No 0.5 0.4 0.3 0.4 0.5 0.5 0.6
diffM&eqV No 5 97.3 94.8 97.2 97.3 97.1 96.8
No 1 91.0 85.7 91.0 89.8 90.2 88.7
No 0.5 87.5 76.7 87.2 85.0 85.3 83.9
eqM&diffV No 5 89.6 18.1 87.3 84.2 82.5 82.1
No 1 75.6 6.3 69.0 63.2 61.2 60.6
No 0.5 69.0 2.7 59.0 54.0 51.7 51.8
diffM&diffV No 5 84.4 57.0 83.3 80.3 79.8 78.9
No 1 66.1 36.2 63.8 58.4 56.9 56.4
No 0.5 58.9 24.9 55.3 49.0 47.7 47.8
eqM&eqV Yes 5 12.1 3.9 3.5 5.0 5.1 5.1
Yes 1 3.5 0.6 0.5 0.8 0.8 0.9
Yes 0.5 2.0 0.4 0.2 0.5 0.4 0.5
diffM&eqV Yes 5 96.1 95.2 98.4 98.2 98.2 98.4
Yes 1 84.8 82.9 94.9 93.3 94.2 93.2
Yes 0.5 79.5 78.0 91.6 89.3 90.1 88.0
eqM&diffV Yes 5 46.8 16.8 55.0 69.1 67.7 67.8
Yes 1 23.2 3.9 32.8 45.3 46.2 43.5
Yes 0.5 17.7 2.2 24.3 35.7 35.7 32.7
diffM&diffV Yes 5 57.0 59.5 77.7 78.8 79.7 78.4
Yes 1 29.1 32.4 59.9 57.9 60.3 57.3
Yes 0.5 22.0 26.3 50.1 47.9 50.0 46.4
When methylation levels were generated from normal distributions without out-
liers, all tests had their empirical Type I error rates close to the nominal levels,
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except for KS (Table 4.1). For Power Scenarios I, II, and III, three improved joint
score tests had similar performance, but slightly lower power for jointLRT and AW.
When methylation values were from normal distributions with an outlier, the three
improved joint score tests can maintain empirical Type I error rates well at all nom-
inal levels. Whereas the empirical Type I error rates of jointLRT were inflated at
all nominal levels, AW and KS had very conservative empirical Type I error rates
at all levels (Table 4.1). For Power Scenarios I, II and III, the three improved tests
had similar or greater power than AW. For Power Scenarios II and III (i.e., differ-
ent variances), KS had poor estimated power despite the presence or absence of an
outlier. Similar findings of KS were also observed in other parametric distributions
(Tables 4.2 and 4.4).
Similar findings were also observed for the Beta distribution setting (Table 4.2).
When the Beta distributions of two groups were different in variances (Power Sce-
narios II and III) and contained outliers, the three improved tests had significantly
greater power than AW.
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Table 4.2: The type I error (×100) and power (×100) for the six tests evaluated at
5%, 1%, and 0.5% significance levels when methylation β-values were generated from
the beta distribution without or with an outlier. The numbers of non-diseased and
diseased samples are (100, 100).
Scenarios Out Level(%) jointLRT KS AW iAW.Lev iAW.BF iAW.TM
eqM&eqV No 5 5.4 3.6 5.0 5.1 5.3 5.2
No 1 1.1 0.6 0.9 1.0 1.1 0.9
No 0.5 0.6 3.3 0.4 0.5 0.5 0.4
diffM&eqV No 5 97.3 94.9 97.9 97.8 97.7 97.8
No 1 90.8 82.9 92.5 91.0 91.7 92.3
No 0.5 85.3 78.5 89.5 86.4 88.5 88.9
eqM&diffV No 5 88.5 18.4 87.1 82.7 82.1 82.6
No 1 71.0 4.0 68.1 61.1 60.9 63.4
No 0.5 61.8 2.5 58.5 51.1 53.5 56.0
diffM&diffV No 5 84.2 66.0 88.2 85.6 85.9 86.1
No 1 62.8 37.6 71.4 65.1 66.1 69.0
No 0.5 52.5 31.4 63.6 56.2 59.3 62.3
eqM&eqV Yes 5 11.1 3.4 3.8 5.1 5.1 4.7
Yes 1 2.9 0.6 0.5 1.1 0.9 0.9
Yes 0.5 1.7 0.4 0.2 0.5 0.5 0.4
diffM&eqV Yes 5 97.1 95.5 98.7 98.4 98.8 98.8
Yes 1 88.3 84.7 95.4 93.3 94.8 94.3
Yes 0.5 83.1 80.4 92.2 89.1 91.9 91.4
eqM&diffV Yes 5 31.7 15.8 26.3 60.1 59.0 61.1
Yes 1 12.1 3.7 9.4 32.5 31.7 33.8
Yes 0.5 8.0 2.3 4.3 23.1 24.2 25.5
diffM&diffV Yes 5 28.5 59.7 37.7 53.2 52.7 54.4
Yes 1 8.9 33.5 19.7 24.8 26.2 27.0
Yes 0.5 5.8 27.2 12.6 16.4 19.1 19.3
When methylation values were generated from a two-component normal mixture
distribution without outliers, both iAW.BF and AW had appropriate empirical Type
I error rates. However, iAW.Lev and iAW.TM had significantly inflated empirical
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Type I error rates. Additionally, jointLRT and KS had conservative empirical Type
I error rates. Under all Power Scenarios, iAW.BF had greater power than AW
and jointLRT. When methylation values were from two-component normal mixture
distributions with an outlier, iAW.BF had appropriate simulated Type I error rates
at each level. Although iAW.Lev and iAW.TM had increased empirical Type I error
rates, they are much smaller than those rates of jointLRT. The KS and AW tests
had conservative empirical Type I error rates. All of the three improved tests had
significantly greater power than AW under Power scenarios II (i.e., different variances
only) and III (i.e., different means and different variances).
When methylation values were generated from a chi-squared distribution without
outliers, iAW.BF, iAW.TM and AW kept empirical Type I error rates well, though
iAW.Lev presented increased empirical Type I error rates. While jointLRT had
inflated empirical Type I error rates, and KS had more conservative empirical Type
I error rates. For Power scenarios II and III (i.e., different variances), iAW.BF and
iAW.TM had significantly greater power than AW, and iAW.Lev had similar power
to AW for three power scenarios. When methylation values were generated from a
chi-squared distribution with an outlier, the performance of all tests were similar,
with the exception of AW, where it had conservative empirical Type I error rates.
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Table 4.3: The type I error (×100) and power (×100) for the six tests evaluated at 5%, 1%, and
0.5% significance levels when methylation β-values were generated from the mixture of two normal
distributions without or with an outlier. The numbers of non-diseased and diseased samples are
(100, 100).
Scenarios Out Level(%) jointLRT KS AW iAW.Lev iAW.BF iAW.TM
eqM&eqV No 5 2.0 3.6 4.8 9.5 5.2 11.4
No 1 0.5 0.7 0.8 3.0 1.1 4.3
No 0.5 0.2 0.4 0.4 1.8 0.6 2.8
diffM&eqV No 5 98.8 100 97.5 99.0 99.3 98.4
No 1 93.9 99.8 91.9 94.3 97.8 91.0
No 0.5 90.6 99.7 87.8 90.2 96.4 84.6
eqM&diffV No 5 35.0 98.1 54.5 88.9 59.2 75.8
No 1 10.7 81.1 35.6 72.5 36.1 52.7
No 0.5 6.2 72.5 28.7 63.9 28.9 42.5
diffM&diffV No 5 47.3 99.6 56.1 89.8 80.8 82.5
No 1 19.6 93.7 36.9 72.4 60.7 56.5
No 0.5 14.0 91.0 29.7 62.6 52.6 44.8
eqM&eqV Yes 5 24.3 3.4 2.3 5.5 5.2 6.7
Yes 1 6.1 0.6 0.4 1.2 0.8 1.8
Yes 0.5 3.4 0.4 0.2 0.7 0.4 1.0
diffM&eqV Yes 5 90.8 100 98.9 99.5 99.9 99.5
Yes 1 76.4 100 95.1 97.3 98.2 96.3
Yes 0.5 69.0 100 91.6 95.3 97.3 93.9
eqM&diffV Yes 5 0.4 97.5 13.0 81.9 48.1 71.5
Yes 1 0 86.2 5.2 60.4 29.1 45.9
Yes 0.5 0 71.5 3.3 51.0 23.0 37.3
diffM&diffV Yes 5 10.0 99.5 44.8 88.7 80.0 85.0
Yes 1 3.0 96.1 26.3 70.3 61.9 62.5
Yes 0.5 1.8 91.3 18.7 60.7 54.2 52.5
From the results of the four tables, we found that iAW.BF could control empirical
Type I error rates well and have similar or greater power than AW under all scenarios
including the existence of outliers, skewed distributions, and mixtures of two normal
distributions. For the scenarios of mixtures of two normal distributions, iAW.Lev and
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iAW.TM can maintain empirical Type I error rates at proper levels and had similar or
greater power than AW. In comparison, AW can maintain appropriate empirical Type
I error rates for any parametric distributions as designed without outliers. When the
methylation values were generated from a distribution with an outlier, AW tended
to have conservative empirical Type I error rates and smaller estimated power. The
jointLRT, on the other hand, only performed best for methylation values generated
from normal distributions without outliers. KS can keep conservative empirical Type
I error rates under all scenarios, and it had poor estimated power in many scenarios.
Simulation studies were also conducted when the sample size was moderate (50,
50) and small (20, 20). The results are provided in Appendix C. We observed that
empirical Type I error rates increased and power decreased when the sample size
decreased from 100 to 50 subjects per group. Furthermore, the three improved joint
score tests still performed significantly better than AW under a moderate or small
sample size.
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Table 4.4: The type I error (×100) and power (×100) for the six tests evaluated at 5%, 1%, and
0.5% significance levels when methylation β-values were generated from the chi-square distribution
without or with an outlier. The numbers of non-diseased and diseased samples are (100, 100).
Scenarios Out Level(%) jointLRT KS AW iAW.Lev iAW.BF iAW.TM
eqM&eqV No 5 14.4 3.7 4.8 5.9 5.2 4.7
No 1 5.8 0.7 0.8 1.3 0.9 1.0
No 0.5 4.1 0.4 0.4 0.7 0.5 0.5
diffM&eqV No 5 90.5 99.7 99.8 99.7 99.9 99.9
No 1 61.1 96.8 99.0 97.0 99.5 99.4
No 0.5 46.2 95.3 98.1 94.9 99.0 98.9
eqM&diffV No 5 20.6 10.1 27.4 32.0 35.9 35.4
No 1 7.8 2.0 11.4 12.0 17.0 15.6
No 0.5 4.9 1.3 6.8 8.3 11.0 10.3
diffM&diffV No 5 20.7 44.4 61.3 58.1 72.8 68.7
No 1 5.3 18.5 39.4 29.3 49.3 43.3
No 0.5 2.9 14.1 30.5 21.2 39.3 33.9
eqM&eqV Yes 5 20.4 4.0 4.5 6.9 5.2 4.9
Yes 1 10.3 0.6 0.6 1.6 1.0 0.9
Yes 0.5 7.8 0.4 0.3 0.9 0.5 0.4
diffM&eqV Yes 5 71.4 99.6 99.8 99.5 99.9 99.9
Yes 1 24.6 96.3 99.3 95.7 99.4 99.3
Yes 0.5 13.4 94.6 98.7 92.5 98.8 98.6
eqM&diffV Yes 5 29.6 9.4 34.9 38.6 43.0 41.4
Yes 1 10.8 1.8 13.2 16.6 20.5 20.1
Yes 0.5 6.6 1.2 7.7 10.7 14.2 14.3
diffM&diffV Yes 5 23.4 41.3 68.7 61.0 74.9 71.3
Yes 1 6.5 16.2 45.5 32.5 51.7 48.2
Yes 0.5 3.2 12.0 35.6 23.3 42.0 38.4
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4.3 Real Data Analysis
4.3.1 Data description
We applied all six statistical tests to three publicly available DNA methylation
data sets: GSE37020 (Teschendorff and Widschwendter, 2012), GSE20080 (Teschen-
dorff et al., 2010), and GSE107080 (Zhang et al., 2017)) from Gene Expression Om-
nibus (GEO)(www.ncbi.nlm.nih.gov/geo).
The two HM27k data sets GSE37020 and GSE20080 have been described in
Section 3.3.1. The procedures of quality control and preprocessing about the two data
sets are presented in Appendix B. We used clean GSE37020 as the discovery set and
clean GSE20080 as the validation set to detect CpG sites differentially methylated
(DM) or differentially variable (DV) between CIN2+ samples and normal samples.
For a given CpG site in a given data set, we applied each of the six joint tests to
test for equalities of both means and variances. For a given joint test, we claimed a
CpG site in the analysis of GSE37020 as significant methylation candidate (different
in means or variances) if the false discovery rate (FDR) (Benjamini and Hochberg,
1995) adjusted p-value for the CpG site is less than 0.05. The function p.adjust in
the statistical software R was used to calculate the FDR-adjusted p-value. For a
significant site in the analysis of GSE37020, if the corresponding un-adjusted p-value
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in the analysis of GSE20080 is less than 0.05 and the difference in the directions of
means and variances are consistent between the two data sets, then we claim that
the significance in the analysis of GSE37020 is truly validated in the analysis of
GSE20080. We use the differences of medians and mean absolute deviations between
cases and controls to evaluate the directions.
GSE107080 contained DNA methylation profiles of about 850K sites measured
from whole blood samples using Illumina Infinium MethylationEPIC (EPIC) plat-
form. GSE107080 included 100 individuals with illicit drug injection and hepatitis
C type virus (IDU+/HCV+) and 305 individuals without illicit drug injection and
hepatitis C type virus (IDU-/HCV-). All the individuals were recruited from a well-
established longitudinal cohort, Veteran Aging Cohort Study. The procedures of
quality control and preprocessing for GSE107080 are presented in Appendix B.
For dataset GSE107080, the samples were randomly split into two sets of ap-
proximate equal size (due to odd numbers of cases and controls) as the training set
and the validation set. The training set contained 148 controls (IDU-/HCV-) and
48 cases (IDU+/HCV+), and the validation set contained 147 controls and 47 cases.
We used a similar method as the above to determine if the significance of a CpG site
is truly validated.
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4.3.2 Results
For GSE37020, the numbers of significant CpG sites (i.e., CpG sites with FDR-
adjusted p-value < 0.05) obtained by the six joint tests are 4556 (jointLRT), 1288
(KS), 1850 (AW), 2041 (iAW.Lev), 1843 (iAW.BF), and 1838 (iAW.TM). The truly
validated CpG sites are 1705 (jointLRT), 47 (KS), 220 (AW), 666 (iAW.Lev), 296
(iAW.BF), and 342 (iAW.TM).
Table 4.5: The performance of six joint tests based on HM27k data sets
GSE37020 and GSE20080.
Test nSig nValidation nTV pTV(%) nFV pFV(%)
JointLRT 4556 2213 1705 77.0 508 23.0
KS 1288 60 47 78.3 13 21.7
AW 1850 262 220 84.0 42 16.0
iAW.Lev 2041 747 666 89.2 81 10.8
iAW.BF 1843 339 296 87.3 43 12.7
iAW.TM 1838 387 342 88.4 45 11.6
nSig : the number of significant CpG sites detected in GSE37020 (adjusted p-
value < 0.05);
nValidation : the number of validated CpG sites in GSE20080 (unadjusted p-value
< 0.05);
nTV : the number of truly validated CpG sites with the same difference direc-
tions in means and variances between two samples;
pTV : = nTV
nV alidation
, the proportion of significant CpG sites detected in
GSE37020 and truly validated in GSE20080;
nFV : the number of falsely validated CpG sites in GSE20080 with inconsistent
difference direction in means or variances between two samples;
pFV : = nFV
nV alidation
, the proportion of significant CpG sites detected in GSE37020
but falsely validated in GSE20080.
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Table 4.5 presents the numbers/proportions of truly and falsely validated signif-
icant CpG sites. The three improved joint score tests have higher true validation
ratios than joint LRT, KS, and AW. Among all the tests, iAW.Lev had the highest
true validation rate (89.2%) and the lowest false validation rate (10.8%), followed by
iAW.TM and iAW.BF.
Figure 4.1 shows the parallel boxplots of DNA methylation levels versus case-
control status for the top CpG site (i.e., having the smallest p-value among those
truly validated CpG sites for testing the homogeneity of means and variances si-
multaneously) obtained by each of the six joint tests. All these top CpG sites were
validated in GSE20080. It has been found that the high incidence of cervical lesions
is associated with the genes ST6GALNAC3, CRB1 and RGS7, where cg26363196
(jointLRT), cg00321478 (AW) and cg21303386 (iAW.Lev) might reside (Farkas et al.,
2013; Kudela et al., 2016). Furthermore, the gene PRRG2, where cg2196766 (KS)
might reside, is involved in the signal transduction pathway, which might be a novel
biomarker for CIN2+ diagnosis (Yazicioglu et al., 2013). The gene FPRL2, where
cg06784466 (iAW.BF, iAW.TM) might reside, is related to innate immunity and host
defense mechanisms (Devosse et al., 2009).
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Figure 4.1: Paired parallel boxplots of DNA methylation levels (y-axis) versus case-control
status (x-axis) for the 5 unique top CpG sites acquired by the six joint tests based on
HM27k data sets. The dots indicate subjects.1A and 1B are for cg26363196 (jointLRT).
2A and 2B are for cg2196766 (KS). 3A and 3B are for cg00321478 (AW). 4A and 4B are
for cg21303386 (iAW.Lev). 5A and 5B are for cg06784466 (iAW.BF, iAW.TM). 1A, 2A,
3A, 4A, 5A are based on GSE37020. 1B, 2B, 3B, 4B, 5B are based on GSE20080.
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For GSE107080, the number of significant CpG sites (i.e., CpG sites with FDR-
adjusted p-value < 0.05) obtained by the six joint tests in the training set are 51, 994
(jointLRT), 10 (KS), 12 (AW), 709 (iAW.Lev), 22 (iAW.BF), and 22 (iAW.TM).
The corresponding numbers of validated CpG sites in the validation set (i.e., CpG
sites with unadjusted p-value < 0.05) are 19, 806 (jointLRT), 3 (KS), 5 (AW), 201
(iAW.Lev), 7 (iAW.BF), and 9 (iAW.TM). After checking the direction of differences,
the truly validated CpG sites are 5652 (jointLRT), 1 (KS), 2 (AW), 89 (iAW.Lev),
4 (iAW.BF), and 5 (iAW.TM).
Table 4.6 presents the numbers/proportions of truly and falsely validated signif-
icant CpG sites based on GSE107080. The three improved tests have higher true
validation rates than joint LRT, KS and AW tests. Amongst them, iAW.BF and
iAW.TM have a more than ten percent higher proportion of true validation than
AW.
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Table 4.6: The performance of six joint tests based on EPIC data GSE107080.
Test nSig nValidation nTV pTV(%) nFV pFV(%)
JointLRT 51994 19806 5652 28.5 14154 71.5
KS 10 3 1 33.3 2 66.7
AW 12 5 2 40.0 3 60.0
iAW.Lev 709 201 89 44.3 112 55.7
iAW.BF 22 7 4 57.1 3 42.9
iAW.TM 22 9 5 55.6 4 44.4
nSig : the number of significant CpG sites detected in the training set of
GSE107080 (adjusted p-value < 0.05);
nValidation : the number of validated CpG sites in the validation set of
GSE107080 (unadjusted p-value < 0.05);
nTV : the number of truly validated CpG sites with the same difference direc-
tions in means and variances between two samples;
pTV : = nTV
nV alidation
, the proportion of significant CpG sites detected in the
training set and truly validated in the validation set;
nFV : the number of falsely validated CpG sites in the validation set with
inconsistent difference direction in means or variances between two samples;
pFV : = nFV
nV alidation
, the proportion of significant CpG sites detected in the
training set but falsely validated in the validation set.
4.4 Discussion
The three improved joint score tests are derived from the generalized linear model
framework as AW, thus they maintain the strengths of AW in terms of efficiency.
Furthermore, the three improved tests use an absolute deviation instead of a squared
deviation used by AW to enhance the robustness. For skewed methylation distribu-
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tions or distributions with outliers, squared deviation used by AW can be enormously
affected by extreme values, which can lead to erroneous results, thus AW tends to
have conservative empirical Type I error rates and smaller power in some scenarios.
Our proposed methods rectify this problem and thus can maintain good power even
if the distribution is skewed or contains outliers. Furthermore, when compared to the
squared deviation, the absolute deviation retains the same magnitude of the original
measurement scales and are consequently more interpretable. The iAW.Lev tends to
have inflated empirical Type I error rates under skewed and mixture distributions.
In comparison, iAW.BF and iAW.TM employ a median or trimmed mean as the
central tendency to calculate absolute deviation. Both of them are robust and can
minimize the impact of outliers and skewed distributions in evaluating the overall
dispersion of the sample data.
The performance of the jointLRT is highly dependent on the validity of normality
assumptions. However, the empirical distribution of methylation data are often
skewed or contain outlying observations. The KS test is inclined to have conservative
empirical Type I error rates and lowest power under many scenarios. Therefore, it
might not be suitable for DNA methylation analysis as expected.
We would like to address one limitation in our simulation studies. Since the
analytical form of the underlying probability distribution of methylation data is
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rarely known, we have applied various settings in an attempt to mimic the reality. We
also try to evaluate our methods in four different aspects. However, our simulation
study might not cover all the possible cases that one might encounter in reality.
Nevertheless, the results from real data analyses provide strong evidence to support
the thesis that our proposed tests are in general more robust in comparison with the
AW test.
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5 Model-based clustering for detecting
differentially variable microRNAs
Besides DNA methylation, microRNA (miRNA) regulation is another important
epigenetic mechanism. Aberrant miRNA expression pattern has been linked to many
diseases (Lu et al., 2005; Cullen, 2011; Ferna´ndez-Hernando et al., 2013). In addition
to differential mean expression, differentially variable expression levels can also signif-
icantly affect gene regulation. Moreover, the correlations between different miRNAs
can help us advance our understanding of the mechanism of genetic disorders and
find the truly important candidate of miRNAs for diagnoses and therapy.
In this chapter, we focus on better identifying miRNA probes based on their
differential variances by employing the framework of Qiu et al. (2008) and modify-
ing the marginal model to detect differentially variable (DV) miRNAs. We impose
special structures on covariance matrices for each cluster of miRNAs based on prior
information about the relationship between variances in cases and controls.
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5.1 Framework
We assume that the miRNA expression data have been normalized to remove the
confounding effects and transformed so that the distribution of the miRNA expression
levels is close to a normal distribution. Based on Qiu et al. (2008), for a given miRNA,
we denote Xi as the processed expression level for the ith subject, i = 1, . . . ,m, where
m = mc + mn, mc is the number of diseased samples (cases) and mn is the number
of non-diseased samples (controls). Let X = (X1, . . . , Xmc , Xmc+1, . . . , Xmc+mn)
T
denote the processed expression profiles overm samples and follow a three-component
mixture of multivariate normal distributions with marginal density:
pi1f1(x;θ1) + pi2f2(x;θ2) + pi3f3(x;θ3),
pi1 + pi2 + pi3 = 1, pik > 0, k = 1, 2, 3,
(5.1)
where pi1, pi2, pi3 are mixing proportions. The m × 1 vector x is a realization of the
random vector X; θk, is the parameter set for the k-th component distribution fk,
k = 1, 2, 3; and f1, f2, and f3 are the density functions for multivariate normal
distributions with the mean vectors
µ1 =
(
µ1c1mc
µ1n1mn
)
, µ2 =
(
µ2c1mc
µ2n1mn
)
, µ3 =
(
µ3c1mc
µ3n1mn
)
, (5.2)
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and covariance matrices
Σ1 =
(
σ21cR1c 0
0 σ21nR1n
)
, Σ2 =
(
σ22R2c 0
0 σ22R2n
)
,
Σ3 =
(
σ23cR3c 0
0 σ23nR3n
)
,
(5.3)
respectively, where the correlation matrices are
Rt = (1− ρt)
[
Int +
ρt
(1− ρt)1nt1
T
nt
]
, (5.4)
t = 1c, 1n, 2c, 2n, 3c, or 3n. Note that nt = mc if t = 1c, 2c, or 3c; nt = mn if t =
1n, 2n, or 3n. Without loss of generality, we assume the first mc elements are for the
diseased samples (cases) and the remainingmn elements are for the non-diseased sam-
ples (controls). Let θ1 = (µ1c, σ
2
1c, ρ1c, µ1n, σ
2
1n, ρ1n)
T , θ2 = (µ2c, σ
2
2, ρ2c, µ2n, ρ2n)
T ,
θ3 = (µ3c, σ
2
3c, ρ3c, µ3n, σ
2
3n, ρ3n)
T .
We assume that the available miRNAs belong to one and only one of the following
clusters: (1) σ21c > σ
2
1n, miRNAs having higher variances in cases than in controls
(denoted as the OV cluster), (2) σ22c = σ
2
2n = σ
2
2, miRNAs having equal variances
between cases and controls (denoted as the EV cluster), (3) σ23c < σ
2
3n, miRNAs
having smaller variances in cases than in controls (denoted as the UV cluster). We
allow the means and correlations to be different between cases and controls in the
EV cluster.
Based on the characteristics of miRNA expression profiles, Model 5.1 makes some
assumptions to capture the structural information of miRNA expression data: (a)
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miRNA expression profiles in the same cluster have the same marginal distribution;
(b) miRNA expression profiles are marginally independent; (c) marginal means and
variances of expression levels for a given miRNA from the same type of samples (cases
or controls) are the same; (d) marginal correlations between any pair of expression
levels for a given miRNA from the same type of samples are the same; (e) marginal
correlations between any pair of expression levels for a given miRNA from different
types of samples are zero.
Next, we derive a selection method for miRNA candidate based on Model 5.1. The
j-th miRNA is assigned to one of the three clusters based on its posterior probability
Pr(gene j ∈ cluster k|xj) = pikfk(xj;θk)
pi1f1(xj;θ1) + pi2f2(xj;θ2) + pi3f3(xj;θ3)
,
k =1, 2, 3,
(5.5)
where xj is the processed profile for the j-th miRNA, j = 1, . . . , p. It means that
gene j with profile xj will be classified to cluster Ck0 if the posterior probability that
the j-th miRNA belongs to cluster Ck0 given xj is the largest, i.e.,
k0 = arg max
k
Pr(gene j ∈ Ck|xj). (5.6)
5.2 Parameter estimation
Based on Titterington et al. (1985), the complete data can be represented as
{yj, j = 1, . . . , p} = {(xTj , zTj )T , j = 1, . . . , p},
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where p is the number of miRNAs, xj is an m × 1 vector, m = mc + mn, mc is
the number of diseased samples, mn is the number of non-diseased samples, zj =
(z1j, z2j, 1− z1j − z2j) and
zkj =
{
1 if xj is in category k
0 otherwise
, j = 1, . . . , p, k = 1, 2.
Then the likelihood corresponding to (y1, . . . ,yp) can be written as
g(y1, . . . ,yp|Ψ) =
p∏
j=1
f(xj, zj)
=
p∏
j=1
f(xj|zj)f(zj)
=
p∏
j=1
{[
f1(xj)
z1jf2(xj)
z2jf3(xj)
(1−z1j−z2j)] [piz1j1 piz2j2 (1− pi1 − pi2)(1−z1j−z2j)]} ,
where
Zi ∼ Multinomial (1, pi1, pi2, 1− pi1 − pi2) , (5.7)
and
f(zi) =

pi1 if z1j = 1 and z2j = 0,
pi2 if z1j = 0 and z2j = 1,
1− pi1 − pi2 if z1j = z2j = 0,
=pi
z1j
1 pi
z2j
2 (1− pi1 − pi2)(1−z1j−z2j),
(5.8)
and
f(xj|zj) =

f1(xj) if z1j = 1 and z2j = 0,
f2(xj) if z1j = 0 and z2j = 1,
f3(xj) if z1j = z2j = 0,
=f1(xj)
z1jf2(xj)
z2jf3(xj)
(1−z1j−z2j).
(5.9)
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The log complete likelihood function is
`0(Ψ) =
p∑
j=1
zTj V (pi) +
p∑
j=1
zTj Uj(θ),
where
zj =
 z1jz2j
1− z1j − z2j
 , V (pi) =
 log(pi1)log(pi2)
log(1− pi1 − pi2)
 , Uj(θ) =
 log (f1(xj;θ1))log (f2(xj;θ2))
log (f3(xj;θ3))
 ,
and
θ1 =
(
µ1c, σ
2
1c, ρ1c, µ1n, σ
2
1n, ρ1n
)T
,
θ2 =
(
µ2c, σ
2
2, ρ2c, µ2n, ρ2n
)T
,
θ3 =
(
µ3c, σ
2
3c, ρ3c, µ3n, σ
2
3n, ρ3n
)T
,
and
Ψ =
(
pi1, pi2, µ1c, σ
2
1c, ρ1c, µ1n, σ
2
1n, ρ1n, µ2c, σ
2
2, ρ2c, µ2n, ρ2n, µ3c, σ
2
3c, ρ3c, µ3n, σ
2
3n, ρ3n
)T
.
From some initial approximation, the EM algorithm generates Ψ(0), a sequence
{Ψ(t)} of estimates. Each iteration consists of the following two steps:
E-step: Evaluate Q
(
Ψ,Ψ(t)
)
= E
[
log(g(y|Ψ)|x,Ψ(t)].
M-step: Find Ψ = Ψ(t+1) to maximize Q
(
Ψ,Ψ(t)
)
.
The procedures of parameter estimation are presented in Appendix D.
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5.3 Simulation studies
5.3.1 Simulation setting
We conducted four sets of simulation studies. In the first set (denoted as SimI), we
generated miRNA data from the proposed marginal mixture model of multivariate
normal, where estimated model parameters for GSE67139 (i.e., the discovery set)
are used as the true values of the model parameters (pi1 = 0.31, pi2 = 0.58, pi3 =
0.11, µ1c = −0.14, σ21c = 1.49, ρ1c = 0.08, µ1n = 0.14, σ21n = 0.45, ρ1n = 0.32, µ2c =
0.03, σ22c = 1.01, ρ2c = 0.04, µ2n = −0.03, σ22n = 1.01, ρ2n = 0.11, µ3c = 0.13, σ23c =
0.28, ρ3c = 0.04, µ3n = −0.13, σ23n = 1.69, ρ1n = −0.01). We generated 100 data
sets, each of which has 1,000 miRNAs for 50 cases and 50 controls. The numbers of
miRNAs in each cluster are 310 (OV), 580 (EV) and 110 (UV).
In the second set (denoted as SimII), we generated miRNA data from a mixture
of three-component multivariate t distribution with the same mean vectors and co-
variance matrices as those in SimI and with three degrees of freedom. SimII is used
to evaluate the performance of the proposed method when the normality assumption
for any one of the three clusters (OV, EV, and UV) is violated.
In the third set (denoted as SimIII) of the simulation studies, we generated
miRNA data from the same model as that in SimI, except that the marginal corre-
87
lations within subject-groups were set to zero (ρkc = 0 and ρkn=0). SimIII is used
to evaluate the performance of the proposed method when there are no marginal
correlations.
In the fourth set (denoted as SimIV) of the simulation studies, we generated
miRNA data from the same model as that in SimII, except that the marginal corre-
lations within subject-groups were set to zero (ρkc=0 and ρkn = 0). SimIV is used
to evaluate the performance of the proposed method when there are no marginal
correlations and when the normality assumption for any one of the three clusters
(OV, EV, and UV) is violated.
We compared the proposed method (denoted as gs) with the six methods which
are based on Bar et al.’s (2014) N3 model, and Bar and Schifano’s (2018) L2N
model. Both N3 and L2N models have been implemented in R package DVX (Bar
and Schifano, 2018). For both N3 and L2N, DVX outputs raw p-values, q-values, and
posterior probabilities pgk that the probe g belongs to cluster k given its expression
profile and estimated model parameters, k = 1, 2, 3. Hence, for both N3 and L2N,
we used three methods to assign probes to two clusters: DV probes and non-DV
probes. The first method is based on the q-value. If a miRNA has a q-value < 0.05,
we assign that to be differentially variable; and non-differentially variable otherwise.
The second method is based on the false-discovery-rate (FDR) adjusted p-value. If
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a miRNA has a FDR-adjusted p-value < 0.05, we assign that to be differentially
variable; and non-differentially variable otherwise. The third method is based on the
posterior probabilities. We assign a miRNA to cluster k* if the posterior probability
pgk∗ is the largest among the three posterior probabilities, pg1, pg2, and pg3. We
denote the three miRNA-assignment methods as N3.q (L2N.q), N3.f (L2N.f), and
N3 (L2N), respectively.
For simulated datasets, we calculated the magnitude of agreement between the
true cluster memberships of miRNAs and the detected cluster memberships by each
of the seven methods using the Jaccard index (Jaccard, 1912; Qiu et al., 2008).
The maximum value of the Jaccard index is one, indicating perfect agreement. The
minimum value of the Jaccard index is zero, indicating that the agreement is by
chance. The definition of Jaccard index is presented as follows.
Let A and B are two sets, each with p binary attributes, A = {Aj ∈ A|Aj =
0 or 1, j = 1, . . . , p}, B = {Bj ∈ B|Bj = 0 or 1, j = 1, . . . , p}. The total numbers of
each combination of attributes for both A and B are specified as follows:
M11 =
p∑
j=1
I(Aj = 1 and Bj = 1), M01 =
p∑
j=1
I(Aj = 0 and Bj = 1),
M10 =
p∑
j=1
I(Aj = 1 and Bj = 0), M00 =
p∑
j=1
I(Aj = 0 and Bj = 0),
where I(x) is an indicator function, with value as 0 or 1. The Jaccard index is given
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as
J =
M11
M01 +M10 +M11
. (5.10)
We also evaluate the performance using the false positive rate (FPR) (i.e., the
proportion of detected DV probes among the true non-DV probes) and the false
negative rate (FNR) (i.e., the proportion of detected non-DV probes among the true
DV probes). The smaller the FPR (FNR), the better the performance.
5.3.2 Simulation results
When data were generated from a mixture of multivariate normal distributions
(SimI and SimIII), the values of the Jaccard index obtained by the gs method were
close to one (the perfect agreement). Under the assumption of a mixture of mul-
tivariate normal distributions, the gs method performed better than the other six
methods in terms of larger Jaccard index, smaller FPR and smaller FNR (Figure 5.1
and 5.2). The values of FPR and FNR obtained by the gs method were significantly
smaller than those by the other six methods. The results of two-sided Wilcoxon
signed-rank tests of Jaccard index, FPR and FNR are shown in Appendix E.
When data were generated from a mixture of multivariate t distributions (SimII
and SimIV), the gs method had a smaller Jaccard index value than the other six
methods (Figure 5.1 and 5.2). It means that when the simulated miRNA was from
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Figure 5.1: The boxplots of estimated Jaccard indices, FPR, and FNR based on
the 100 simulated datasets in SimI. The closer to one the Jaccard index, the better
the performance of the method. The closer to zero the FPR (FNR), the better the
performance of the method.
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Figure 5.2: The boxplots of estimated Jaccard indices, FPR, and FNR based on the
100 simulated datasets in SimIII. The closer to one the Jaccard index, the better
the performance of the method. The closer to zero the FPR (FNR), the better the
performance of the method.
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the multivariate non-normal distribution, the gs method has a higher probability
of classifying them into the wrong sets (DV and non-DV). The gs method had a
smaller FNR but larger FPR values than the other six methods (Figure 5.1 and
5.2). This result shows that when the underlying assumption that the marginal
miRNA expression levels are from multivariate normal distributions is violated, the
gs method may uncover more false miRNA candidates .
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Figure 5.3: The boxplots of estimated Jaccard indices, FPR, and FNR based on
the 100 simulated datasets in SimII. The closer to one the Jaccard index, the better
the performance of the method. The closer to zero the FPR (FNR), the better the
performance of the method.
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Figure 5.4: The boxplots of estimated Jaccard indices, FPR, and FNR based on the
100 simulated datasets in SimIV. The closer to one the Jaccard index, the better
the performance of the method. The closer to zero the FPR (FNR), the better the
performance of the method.
5.4 Real data analysis
5.4.1 Data description
We downloaded two miRNA data sets from online database GEO: GSE67138
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67138) and GSE67139
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67139). Both data sets
are from the same project that aims to detect miRNAs that are differentially ex-
pressed between human hepatocellular carcinoma (HCC) tumor tissues with and
without vascular invasion. GSE67138 is the first batch containing 57 samples (34
invasive tumor tissues and 23 non-invasive tumor tissues), while GSE67139 is the
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second batch containing 120 samples (60 invasive tumor tissues and 60 non-invasive
tumor tissues). The expression levels of miRNAs in both GEO datasets were mea-
sured by using Affymetrix Multispecies miRNA-1 Array (GPL8786). Both datasets
contain 847 miRNAs. Since both data sets have been normalized, we used the two
data sets directly in the further analyses. Since GSE67139 has a larger sample size
than GSE61738, we regarded GSE67139 as the discovery set and GSE67138 as the
validation set.
Following Qiu et al.’s (2008) data preprocessing steps, we first performed the Box-
Cox transformation and miRNA-profile scaling on the two miRNA expression data
sets. We then applied the seven methods (the gs method and the six existing model-
based methods) to the discovery set (GSE67139) to detect miRNAs differentially
variable between invasive tumors and non-invasive tumors. If a miRNA is assigned
to the OV or UV clusters based on the seven model-based clustering methods, we
claim that this miRNA has significantly different variances between invasive tumors
and non-invasive tumors. We then applied the same procedure to the validation set
(GSE67138). We claim that a miRNA is a validated DV miRNA (1) if the miRNA
is DV in both discovery and validation sets, and (2) if the sign of the difference
(s2c−s2n) is the same in both datasets, where s2c and s2n are sample variances for cases
and controls, respectively. We next calculated the proportion of the validated DV
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miRNAs (i.e., validation rate) pV alid = nV alid
nSig
, where nSig is the number of DV
miRNAs in the discovery set (GSE67139) and nV alid is the number of DV miRNAs
significant and sharing the same difference direction of variances in both data sets. To
estimate the variation of the validation rate pV alid, we obtained the 100 bootstrap
validation rates based on 100 bootstrap discovery sets and validation sets. We then
tested to see if the median bootstrap validation rate of the gs method is the same as
that of each of the other six methods by using two-sided Wilcoxon signed-rank tests.
5.4.2 Results
The numbers of the DV miRNAs in the discovery set (GSE67139) and the num-
bers and proportions of the validated DV miRNAs were shown in Table 5.1. The
gs method detected 358 DV probes based on the discovery set (GSE67139), 67 of
which were validated in the validation set (GSE67138). Amongst the 67 validated
DV miRNAs, 66 miRNAs were in Cluster OV and only one miRNA was in Cluster
UV. The proportion of the validated DV miRNAs is 0.19 for the gs method, which
is higher than those of the N3 and L2N methods. Moreover, the gs method had the
highest median bootstrap validation rate among all seven methods (Figure 5). For
all the seven methods, the number of validated OV miRNAs (nValid.OV) was much
higher than the number of validated UV miRNAs (nValid.UV). This observation
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is consistent with that observed by other researchers using DNA methylation data
(Teschendorff and Widschwendter, 2012).
Table 5.1: The performance of model-based clustering methods on miRNA
expression data sets GSE67139 and GSE67138.
Method nSig n.OV n.UV nValid nValid.OV nValid.UV pValid
gs 358 262 96 67 66 1 0.19
L2N.pp 225 121 104 30 29 1 0.13
L2N.q 173 69 104 17 16 1 0.10
L2N.f 157 60 97 16 15 1 0.10
N3.pp 247 141 106 34 33 1 0.14
N3.q 202 96 106 25 24 1 0.12
N3.f 178 74 104 18 17 1 0.10
nSig : the number of DV miRNAs detected in the discovery set (GSE67139);
n.OV : the number of OV miRNAs detected in GSE67139;
n.UV : the number of UV miRNAs detected in GSE67139;
nValid : the number of validated DV miRNAs in the validation set (GSE67138);
nValid.OV : the number of validated OV miRNAs in GSE67138;
nValid.UV : the number of validated UV miRNAs in GSE67138;
pValid : = nV alidnSig , the proportion of significant DV miRNAs detected in GSE67139 and
truly validated in GSE67138.
The gs method detected 67 validated differentially variated miRNAs (66 OV
and 1 UV), seven of which are only differential in variances. The seven DV-only
miRNAs are hsa-miR-1826, hsa-miR-191, hsa-miR-194-star, hsa-miR-222, hsa-miR-
502-3p, hsa-miR-93, and hsa-miR-99b. With the exception of hsa-miR-1826, all
DV-only miRNAs have been associated with HCC. Elyakim et al. (2010) showed
that miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy.
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Figure 5.5: The boxplots of validation rates based on 100 bootstrap samples.
Law and Wong (2011) reported the association of miR-194 with metastatic behavior
of HCC. Murakami et al. (2006) reported that miR-222 is increased in poorly versus
moderately versus well-differentiated hepatomas. Jin et al. (2016) reported that miR-
502-3p suppressed cell proliferation, migration, and invasion in HCC by targeting
SET. Li et al. (2009) confirmed that the miR-106b-25 cluster, which miR-93 belongs
to, is over-expressed in HCC. Morishita et al. (2016) found that miR-99b is up-
regulated in HBV-infected HCC cells.
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Based on the miRSystem analysis, there are 1,639 genes targeted by the identified
seven DV-only miRNAs. These 1,639 genes are in six Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathways: CALCIUM SIGNALING PATHWAY, SALIVARY
SECRETION, AMYOTROPHIC LATERAL SCLEROSIS (ALS), MAPK SIGNAL-
ING PATHWAY, PPAR SIGNALING PATHWAY, and ALZHEIMER’S DISEASE.
All of these six pathways have been linked to HCC in the literature. For example,
Huang et al. (2017) reported that increased mitochondrial fission induced cytosolic
calcium signaling in HCC cells. Chen et al. (2017) reported that in a mice study,
DNA methylation marks that are differentially methylated between livers with HCC
and livers without HCC are enriched in the SALIVARY SECRETION pathway. Seol
et al. (2016)’s results suggest that Riluzole, an amyotrophic lateral sclerosis (ALS)
drug, has an anti-cancer effect on HCC. Feng et al. (2018) reported that cantharidic
acid inhibits HCC cell proliferation by inducing cell apoptosis through the p38 MAPK
signaling pathway. Nwosu et al. (2017) reported that down-regulated genes (HCC
vs. non-HCC) were enriched in PPAR SIGNALING PATHWAY based on each of
the eight HCC datasets downloaded from the Gene Expression Omnibus (GEO). Jin
et al. (2015) reported that Kynurenine 3-monooxygenase (KMO), an enzyme play-
ing a critical role in Huntingtons and Alzheimers diseases, exhibits tumor-promoting
effects toward HCC. Hence, DV-only miRNAs are biologically relevant to HCC.
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5.5 Discussion
In this chapter, we propose a novel model-based clustering method (the gs method)
to detect miRNAs that have different variances between cases and controls. We im-
pose special structures on covariance matrices for each cluster of miRNAs based
on prior information about the relationship between variances of cases and controls.
The proposed method is different from probe-wise equal-variance tests in that it does
not involve hypothesis testing. The real data analysis shows that the gs method has
a larger median bootstrap validation rate than the six existing model-based equal-
variance detecting methods. The simulation studies show that the gs method out-
performs the six existing model-based detection methods if the miRNA expression
data follow a mixture of multivariate normal distributions.
Several model-based clustering algorithms have been proposed to detect differ-
ential variable genetic probes in the literature, such as the N3 methods (Bar et al.,
2014) and the L2N methods (Bar and Schifano, 2018). The N3 methods and L2N
methods do not seem to work as well as the gs method when the underlying distribu-
tion of miRNA expression levels is multivariate normal. The poor performance of N3
and L2N is probably due to the fact that the gs method directly models the observed
expression levels to avoid losing information, while the N3 and L2N methods model
the summary statistics (e.g., mean, variance, or difference of means). Moreover,
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the N3 and L2N methods apply a couple of approximations to derive the marginal
densities, while approximations might cause deviations from true marginal densities.
In summary, the proposed gs method assumes expression levels from the mixture
of multivariate normal distributions. The proposed gs method performs better than
the other model-based methods if the underlying assumption is satisfied.
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6 Conclusion and future work
In this chapter, we summarize the results of this dissertation and discuss some
directions for future research.
First, we propose a new method to cluster high-dimensional protein sequences
and apply it to influenza A H3N2 hemagglutinin sequences. After the entropy-based
dimensionality reduction, the 1960 protein sequences active from 1998 to 2012 are
aggregated into 23 clusters using the Hamming Distance vector algorithm. Based on
these clusters, we investigate the relationship between past vaccines and the dominant
cluster in each influenza season. We find that the dominant flu clusters replace one
another every 2-5 years. The dominant clusters are not periodic within the time
span. Once the HA cluster evolves away from a given region of the sequence space,
it does not reoccur within that region. Furthermore, the dominant clusters often
diverge from the clusters housing vaccine strains.
One possible research is to improve on the Hamming Distance vector algorithm
into the algorithm of clustering categorical data and continuous data simultaneously.
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Such an improved algorithm will enable us to consider more information about amino
acids and provide more details about the resulting evolutionary pattern. Further-
more, we can introduce an amino acid substitution model (Dang et al., 2010) and
epidemiological model (Du et al., 2017) to integrate the genetic information and
transmission information of the influenza virus. This integration can help us fore-
cast the flu epidemic dynamics and design more effective future vaccines.
For DNA methylation studies, we propose three robust joint score tests. We
make extensive comparisons among the three proposed tests with jointLRT, KS test,
and the AW test. Systematic simulation studies show that at least one of the three
proposed tests perform better (i.e., having larger power, while keeping nominal Type
I error rates) than the existing tests for data with outliers or from non-normal dis-
tributions. The analyses of the three real data sets demonstrate that the three
proposed tests have higher true validation rates than those from jointLRT, KS, and
AW. The three proposed joint score tests are robust against the violation of normal-
ity assumption and the presence of outlying observations in comparison with three
existing tests. Among the three proposed tests, iAW.BF seems to be the most robust
and effective one for all simulated scenarios and also in real data analyses. More-
over, we conduct systematic simulation studies and real data analysis to compare the
performance of seven statistical tests for equal-variance hypothesis on DNA methy-
102
lation data, including two tests that were recently proposed in the literature. Our
results show that the Brown-Forsythe test and trimmed-mean-based Levene’s test
have good performance in testing for equal variance in our simulation studies and
real data analysis.
Since the AW-type joint test is derived from the generalized linear regression
model, it can be naturally generalized to incorporate covariates (Ahn and Wang,
2013). It has been demonstrated that many other factors, such as age, gender, race,
can contribute to aberrant DNA methylation pattern (Phipson and Oshlack, 2014;
Zhang et al., 2011). These factors can confound the effect of DNA methylation
on diseases. To identify the true methylation sites associated with the disease of
interest, we need to evaluate and adjust the effects of these confounding factors via
appropriate methods (Teschendorff and Relton, 2018). Moreover, we can consider the
correlations between CpG sites within a genomic region, such as the region nearby
an important promoter. Under the framework of the generalized linear model, our
proposed methods can extend beyond investigating one CpG site to the region-based
analysis.
For studies of miRNA expression data, we propose a novel model-based clustering
method (the gs method) to detect differentially variable miRNAs between cases and
controls. We impose special structures on covariance matrices for each cluster of
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miRNAs based on prior information about the relationship between variances in
cases and controls. This method is different from probe-wise equal-variance tests in
that it does not involve hypothesis testing. The simulation studies show that this
method outperforms other model-based methods if the underlying assumption that
the miRNA expression levels follow a mixture of multivariate normal distributions.
The real data analysis shows that the gs method has a larger median bootstrap
validation rate than the other model-based methods.
The proposed gs method has been demonstrated to rely on the normality as-
sumption. Since it is common to have outliers in miRNA expression data, we intend
to employ a broader family of distribution, Pearson type VII distribution (Pearson,
1916; Sun et al., 2010), to replace the multivariate normal distribution. Since the
Pearson type VII distribution includes Student t-distribution and has heavy tails,
the method based on the marginal model of Pearson type VII distribution can im-
prove the detecting power when outliers are present (Sun et al., 2010). We could
improve the gs method into a robust version against the violation of the normality
assumption on the component distributions. We could also consider detecting dif-
ferentially expressed (DE) and differentially variated (DV) miRNAs simultaneously
using a nine-component multivariate normal mixture model.
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A Additional simulation results in Chapter 3
Table A.1: Ranks of the seven equal-variance tests in terms of power for
simulation scenarios of sample size 200.
n Distribution eqMean Outlier F Bartlett Levene L.trim BF PO.AD PO.SQ
200 N yes no 2 2 5.5 5.5 5.5 5.5 2
200 N yes yes - - - 2.5 2.5 - 1
200 N no no 2 2 5.5 5.5 5.5 5.5 2
200 N no yes - - - 2.5 2.5 - 1
200 c.N no no 4 4 4.0 4.0 4.0 4.0 4
200 c.N no yes - - - 2.0 2.0 2.0 -
200 t yes no - - 2.0 4.0 5.0 3.0 1
200 t yes yes - - 2.0 3.0 4.0 1.0 5
200 t no no - - - 1.0 2.0 - 3
200 t no yes - - - - - - 1
200 chisq yes no - - - - 1.0 - 2
200 chisq yes yes - - - 1.0 2.0 - 3
200 chisq no no - - - - - - 1
200 chisq no yes - - - 1.0 2.0 - 3
200 c.chisq no no - - - - 1.0 - 2
200 c.chisq no yes - - - 1.5 1.5 - 3
“-” : no power can be considered because the test has inflated type I error rates for all the
scenarios in the situation.
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Table A.2: Ranks of the seven equal-variance tests in terms of power for
simulation scenarios of sample size 50.
n Distribution eqMean Outlier F Bartlett Levene L.trim BF PO.AD PO.SQ
50 N yes no 1.5 1.5 - 4.0 5.0 - 3.0
50 N yes yes - - 2 3.0 4.0 1 5.0
50 N no no 1.5 1.5 - 4.0 5.0 - 3.0
50 N no yes - - - 2.0 3.0 1 4.0
50 c.N no no 1.5 1.5 - 4.0 5.0 - 3.0
50 c.N no yes - - - - 1.0 - -
50 t yes no - - - 1.0 2.0 - 3.0
50 t yes yes - - 2 3.5 3.5 1 5.0
50 t no no - - - 1.0 2.0 - 3.0
50 t no yes - - - 1.0 2.0 - 3.0
50 chisq yes no - - - - 1.5 - 1.5
50 chisq yes yes - - - 1.0 2.0 - 3.0
50 chisq no no - - - - - - 1.0
50 chisq no yes - - - 1.0 2.0 - 3.0
50 c.chisq no no - - - - 1.0 - 2.0
50 c.chisq no yes - - - 1.0 2.0 - 3.0
“-” : no power can be considered because the test has inflated type I error rates for all the
scenarios in the situation.
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Table A.3: Ranks of the seven equal-variance tests in terms of power for
simulation scenarios of sample size 20.
n Distribution eqMean Outlier F Bartlett Levene L.trim BF PO.AD PO.SQ
20 N yes no 1.5 1.5 - 4 5 - 3
20 N yes yes - - - 2 3 1 4
20 N no no 1.5 1.5 - 4 5 - 3
20 N no yes - - - 2 3 1 4
20 c.N no no 1.5 1.5 - 4 5 - 3
20 c.N no yes - - - - 1 - -
20 t yes no - - - 1 2 - 3
20 t yes yes - - 2 4 4 1 4
20 t no no - - - 1 2 - 3
20 t no yes - - - 2 3 1 4
20 chisq yes no - - - - 1 - -
20 chisq yes yes - - - 1 2 - 3
20 chisq no no - - - - - - -
20 chisq no yes - - - 1 2 - 3
20 c.chisq no no - - - - 1 - 2
20 c.chisq no yes - - - 1 2 - 3
“-” : no power can be considered because the test has inflated type I error rates for all the
scenarios in the situation.
Table A.4: Number of scenarios with inflated type I error rate and median of ranks
for the seven tests from 48 simulated comparisons.
F Bartlett Levene L.trim BF PO.AD PO.SQ
nreject 39 39 40 12 4 35 5
m 1.5 1.5 2.5 2.0 2.0 1.0 3.0
nreject : number of scenarios where the test has inflated type I error rate;
m : the median of the ranks of the power. For ranks with ties, average ranks were used.
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B Quality control and data preprocessing in
Chapters 3 and 4
QC and data preprocessing of HM27k data sets GSE30760
and GSE20080
GSE37020 contains a total of 48 samples, 24 of which have normal histology and
the remaining are cervical intraepithelial neoplasia of grade 2 or higher (CIN2+). All
of them are human papillomavirus (HPV) positive. Normal and CIN2+ samples are
age-matched. GSE20080 also contains 48 samples. A total of 30 samples (11 HPV
positive samples and 19 HPV negative samples) have normal cytology. The other 18
samples (all HPV positive) are with CIN2+. Moreover, normal and CIN2+ samples
were age-matched.
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Figure B.1: The plot of quantiles across arrays.
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Figure B.2: The plot of the first principal component (PC1) versus the second principal
component (PC2) for DNA methylation data.
For both of the data sets, we excluded some CpG sites residing on SNPs or
with missing values. Quantile plots and principal component analysis did not show
obvious patterns (see Figures B.1 and B.2). After quality control steps, GSE37020
has 23,066 CpG sites, and GSE20080 has 23,255 CpG sites. There are 22,859 CpG
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sites in common between the two data sets. We used these 22,859 CpG sites in our
real data analysis.
QC and preprocessing of Illumina MethylationEPIC data
For EPIC data GSE107080, we downloaded the processed data set from GEO
database (Zhang et al., 2017). We first removed the CpG sites with at least one
missing value or with probe name using “ch” as the prefix. Second, CpG sites with
detection p-values larger than or equal to 10−12 are discarded. There are 378, 808
CpG sites in the clean data set. We drew the plot of quantiles across arrays for
the clean GSE107080 data set. The results did not show any obvious patterns (see
Figure B.3).
0 .
0
0 .
2
0 .
4
0 .
6
0 .
8
1 .
0
Trajectory of quantiles
B e
t a
− v
a
l u
e
G
S M
2 8
6 0
6 4
1
G
S M
2 8
6 0
6 4
2
G
S M
2 8
6 0
6 4
3
G
S M
2 8
6 0
6 4
4
G
S M
2 8
6 0
6 4
5
G
S M
2 8
6 0
6 4
6
G
S M
2 8
6 0
6 4
7
G
S M
2 8
6 0
6 4
8
G
S M
2 8
6 0
6 4
9
G
S M
2 8
6 0
6 5
0
G
S M
2 8
6 0
6 5
1
G
S M
2 8
6 0
6 5
2
G
S M
2 8
6 0
6 5
3
G
S M
2 8
6 0
6 5
4
G
S M
2 8
6 0
6 5
5
G
S M
2 8
6 0
6 5
6
G
S M
2 8
6 0
6 5
7
G
S M
2 8
6 0
6 5
8
G
S M
2 8
6 0
6 5
9
G
S M
2 8
6 0
6 6
0
G
S M
2 8
6 0
6 6
1
G
S M
2 8
6 0
6 6
2
G
S M
2 8
6 0
6 6
3
G
S M
2 8
6 0
6 6
4
G
S M
2 8
6 0
6 6
5
G
S M
2 8
6 0
6 6
6
G
S M
2 8
6 0
6 6
7
G
S M
2 8
6 0
6 6
8
G
S M
2 8
6 0
6 6
9
G
S M
2 8
6 0
6 7
0
G
S M
2 8
6 0
6 7
1
G
S M
2 8
6 0
6 7
2
G
S M
2 8
6 0
6 7
3
G
S M
2 8
6 0
6 7
4
G
S M
2 8
6 0
6 7
5
G
S M
2 8
6 0
6 7
6
G
S M
2 8
6 0
6 7
7
G
S M
2 8
6 0
6 7
8
G
S M
2 8
6 0
6 7
9
G
S M
2 8
6 0
6 8
0
G
S M
2 8
6 0
6 8
1
G
S M
2 8
6 0
6 8
2
G
S M
2 8
6 0
6 8
3
G
S M
2 8
6 0
6 8
4
G
S M
2 8
6 0
6 8
5
G
S M
2 8
6 0
6 8
6
G
S M
2 8
6 0
6 8
7
G
S M
2 8
6 0
6 8
8
G
S M
2 8
6 0
6 8
9
G
S M
2 8
6 0
6 9
0
G
S M
2 8
6 0
6 9
1
G
S M
2 8
6 0
6 9
2
G
S M
2 8
6 0
6 9
3
G
S M
2 8
6 0
6 9
4
G
S M
2 8
6 0
6 9
5
G
S M
2 8
6 0
6 9
6
G
S M
2 8
6 0
6 9
7
G
S M
2 8
6 0
6 9
8
G
S M
2 8
6 0
6 9
9
G
S M
2 8
6 0
7 0
0
G
S M
2 8
6 0
7 0
1
G
S M
2 8
6 0
7 0
2
G
S M
2 8
6 0
7 0
3
G
S M
2 8
6 0
7 0
4
G
S M
2 8
6 0
7 0
5
G
S M
2 8
6 0
7 0
6
G
S M
2 8
6 0
7 0
7
G
S M
2 8
6 0
7 0
8
G
S M
2 8
6 0
7 0
9
G
S M
2 8
6 0
7 1
0
G
S M
2 8
6 0
7 1
1
G
S M
2 8
6 0
7 1
2
G
S M
2 8
6 0
7 1
3
G
S M
2 8
6 0
7 1
4
G
S M
2 8
6 0
7 1
5
G
S M
2 8
6 0
7 1
6
G
S M
2 8
6 0
7 1
7
G
S M
2 8
6 0
7 1
8
G
S M
2 8
6 0
7 1
9
G
S M
2 8
6 0
7 2
0
G
S M
2 8
6 0
7 2
1
G
S M
2 8
6 0
7 2
2
G
S M
2 8
6 0
7 2
3
G
S M
2 8
6 0
7 2
4
G
S M
2 8
6 0
7 2
5
G
S M
2 8
6 0
7 2
6
G
S M
2 8
6 0
7 2
7
G
S M
2 8
6 0
7 2
8
G
S M
2 8
6 0
7 2
9
G
S M
2 8
6 0
7 3
0
G
S M
2 8
6 0
7 3
1
G
S M
2 8
6 0
7 3
2
G
S M
2 8
6 0
7 3
3
G
S M
2 8
6 0
7 3
4
G
S M
2 8
6 0
7 3
5
G
S M
2 8
6 0
7 3
6
G
S M
2 8
6 0
7 3
7
G
S M
2 8
6 0
7 3
8
G
S M
2 8
6 0
7 3
9
G
S M
2 8
6 0
7 4
0
G
S M
2 8
6 0
7 4
1
G
S M
2 8
6 0
7 4
2
G
S M
2 8
6 0
7 4
3
G
S M
2 8
6 0
7 4
4
G
S M
2 8
6 0
7 4
5
G
S M
2 8
6 0
7 4
6
G
S M
2 8
6 0
7 4
7
G
S M
2 8
6 0
7 4
8
G
S M
2 8
6 0
7 4
9
G
S M
2 8
6 0
7 5
0
G
S M
2 8
6 0
7 5
1
G
S M
2 8
6 0
7 5
2
G
S M
2 8
6 0
7 5
3
G
S M
2 8
6 0
7 5
4
G
S M
2 8
6 0
7 5
5
G
S M
2 8
6 0
7 5
6
G
S M
2 8
6 0
7 5
7
G
S M
2 8
6 0
7 5
8
G
S M
2 8
6 0
7 5
9
G
S M
2 8
6 0
7 6
0
G
S M
2 8
6 0
7 6
1
G
S M
2 8
6 0
7 6
2
G
S M
2 8
6 0
7 6
3
G
S M
2 8
6 0
7 6
4
G
S M
2 8
6 0
7 6
5
G
S M
2 8
6 0
7 6
6
G
S M
2 8
6 0
7 6
7
G
S M
2 8
6 0
7 6
8
G
S M
2 8
6 0
7 6
9
G
S M
2 8
6 0
7 7
0
G
S M
2 8
6 0
7 7
1
G
S M
2 8
6 0
7 7
2
G
S M
2 8
6 0
7 7
3
G
S M
2 8
6 0
7 7
4
G
S M
2 8
6 0
7 7
5
G
S M
2 8
6 0
7 7
6
G
S M
2 8
6 0
7 7
7
G
S M
2 8
6 0
7 7
8
G
S M
2 8
6 0
7 7
9
G
S M
2 8
6 0
7 8
0
G
S M
2 8
6 0
7 8
1
G
S M
2 8
6 0
7 8
2
G
S M
2 8
6 0
7 8
3
G
S M
2 8
6 0
7 8
4
G
S M
2 8
6 0
7 8
5
G
S M
2 8
6 0
7 8
6
G
S M
2 8
6 0
7 8
7
G
S M
2 8
6 0
7 8
8
G
S M
2 8
6 0
7 8
9
G
S M
2 8
6 0
7 9
0
G
S M
2 8
6 0
7 9
1
G
S M
2 8
6 0
7 9
2
G
S M
2 8
6 0
7 9
3
G
S M
2 8
6 0
7 9
4
G
S M
2 8
6 0
7 9
5
G
S M
2 8
6 0
7 9
6
G
S M
2 8
6 0
7 9
7
G
S M
2 8
6 0
7 9
8
G
S M
2 8
6 0
7 9
9
G
S M
2 8
6 0
8 0
0
G
S M
2 8
6 0
8 0
1
G
S M
2 8
6 0
8 0
2
G
S M
2 8
6 0
8 0
3
G
S M
2 8
6 0
8 0
4
G
S M
2 8
6 0
8 0
5
G
S M
2 8
6 0
8 0
6
G
S M
2 8
6 0
8 0
7
G
S M
2 8
6 0
8 0
8
G
S M
2 8
6 0
8 0
9
G
S M
2 8
6 0
8 1
0
G
S M
2 8
6 0
8 1
1
G
S M
2 8
6 0
8 1
2
G
S M
2 8
6 0
8 1
3
G
S M
2 8
6 0
8 1
4
G
S M
2 8
6 0
8 1
5
G
S M
2 8
6 0
8 1
6
G
S M
2 8
6 0
8 1
7
G
S M
2 8
6 0
8 1
8
G
S M
2 8
6 0
8 1
9
G
S M
2 8
6 0
8 2
0
G
S M
2 8
6 0
8 2
1
G
S M
2 8
6 0
8 2
2
G
S M
2 8
6 0
8 2
3
G
S M
2 8
6 0
8 2
4
G
S M
2 8
6 0
8 2
5
G
S M
2 8
6 0
8 2
6
G
S M
2 8
6 0
8 2
7
G
S M
2 8
6 0
8 2
8
G
S M
2 8
6 0
8 2
9
G
S M
2 8
6 0
8 3
0
G
S M
2 8
6 0
8 3
1
G
S M
2 8
6 0
8 3
2
G
S M
2 8
6 0
8 3
3
G
S M
2 8
6 0
8 3
4
G
S M
2 8
6 0
8 3
5
G
S M
2 8
6 0
8 3
6
G
S M
2 8
6 0
8 3
7
G
S M
2 8
6 0
8 3
8
G
S M
2 8
6 0
8 3
9
G
S M
2 8
6 0
8 4
0
G
S M
2 8
6 0
8 4
1
G
S M
2 8
6 0
8 4
2
G
S M
2 8
6 0
8 4
3
G
S M
2 8
6 0
8 4
4
G
S M
2 8
6 0
8 4
5
G
S M
2 8
6 0
8 4
6
G
S M
2 8
6 0
8 4
7
G
S M
2 8
6 0
8 4
8
G
S M
2 8
6 0
8 4
9
G
S M
2 8
6 0
8 5
0
G
S M
2 8
6 0
8 5
1
G
S M
2 8
6 0
8 5
2
G
S M
2 8
6 0
8 5
3
G
S M
2 8
6 0
8 5
4
G
S M
2 8
6 0
8 5
5
G
S M
2 8
6 0
8 5
6
G
S M
2 8
6 0
8 5
7
G
S M
2 8
6 0
8 5
8
G
S M
2 8
6 0
8 5
9
G
S M
2 8
6 0
8 6
0
G
S M
2 8
6 0
8 6
1
G
S M
2 8
6 0
8 6
2
G
S M
2 8
6 0
8 6
3
G
S M
2 8
6 0
8 6
4
G
S M
2 8
6 0
8 6
5
G
S M
2 8
6 0
8 6
6
G
S M
2 8
6 0
8 6
7
G
S M
2 8
6 0
8 6
8
G
S M
2 8
6 0
8 6
9
G
S M
2 8
6 0
8 7
0
G
S M
2 8
6 0
8 7
1
G
S M
2 8
6 0
8 7
2
G
S M
2 8
6 0
8 7
3
G
S M
2 8
6 0
8 7
4
G
S M
2 8
6 0
8 7
5
G
S M
2 8
6 0
8 7
6
G
S M
2 8
6 0
8 7
7
G
S M
2 8
6 0
8 7
8
G
S M
2 8
6 0
8 7
9
G
S M
2 8
6 0
8 8
0
G
S M
2 8
6 0
8 8
1
G
S M
2 8
6 0
8 8
2
G
S M
2 8
6 0
8 8
3
G
S M
2 8
6 0
8 8
4
G
S M
2 8
6 0
8 8
5
G
S M
2 8
6 0
8 8
6
G
S M
2 8
6 0
8 8
7
G
S M
2 8
6 0
8 8
8
G
S M
2 8
6 0
8 8
9
G
S M
2 8
6 0
8 9
0
G
S M
2 8
6 0
8 9
1
G
S M
2 8
6 0
8 9
2
G
S M
2 8
6 0
8 9
3
G
S M
2 8
6 0
8 9
4
G
S M
2 8
6 0
8 9
5
G
S M
2 8
6 0
8 9
6
G
S M
2 8
6 0
8 9
7
G
S M
2 8
6 0
8 9
8
G
S M
2 8
6 0
8 9
9
G
S M
2 8
6 0
9 0
0
G
S M
2 8
6 0
9 0
1
G
S M
2 8
6 0
9 0
2
G
S M
2 8
6 0
9 0
3
G
S M
2 8
6 0
9 0
4
G
S M
2 8
6 0
9 0
5
G
S M
2 8
6 0
9 0
6
G
S M
2 8
6 0
9 0
7
G
S M
2 8
6 0
9 0
8
G
S M
2 8
6 0
9 0
9
G
S M
2 8
6 0
9 1
0
G
S M
2 8
6 0
9 1
1
G
S M
2 8
6 0
9 1
2
G
S M
2 8
6 0
9 1
3
G
S M
2 8
6 0
9 1
4
G
S M
2 8
6 0
9 1
5
G
S M
2 8
6 0
9 1
6
G
S M
2 8
6 0
9 1
7
G
S M
2 8
6 0
9 1
8
G
S M
2 8
6 0
9 1
9
G
S M
2 8
6 0
9 2
0
G
S M
2 8
6 0
9 2
1
G
S M
2 8
6 0
9 2
2
G
S M
2 8
6 0
9 2
3
G
S M
2 8
6 0
9 2
4
G
S M
2 8
6 0
9 2
5
G
S M
2 8
6 0
9 2
6
G
S M
2 8
6 0
9 2
7
G
S M
2 8
6 0
9 2
8
G
S M
2 8
6 0
9 2
9
G
S M
2 8
6 0
9 3
0
G
S M
2 8
6 0
9 3
1
G
S M
2 8
6 0
9 3
2
G
S M
2 8
6 0
9 3
3
G
S M
2 8
6 0
9 3
4
G
S M
2 8
6 0
9 3
5
G
S M
2 8
6 0
9 3
6
G
S M
2 8
6 0
9 3
7
G
S M
2 8
6 0
9 3
8
G
S M
2 8
6 0
9 3
9
G
S M
2 8
6 0
9 4
0
G
S M
2 8
6 0
9 4
1
G
S M
2 8
6 0
9 4
2
G
S M
2 8
6 0
9 4
3
G
S M
2 8
6 0
9 4
4
G
S M
2 8
6 0
9 4
5
G
S M
2 8
6 0
9 4
6
G
S M
2 8
6 0
9 4
7
G
S M
2 8
6 0
9 4
8
G
S M
2 8
6 0
9 4
9
G
S M
2 8
6 0
9 5
0
G
S M
2 8
6 0
9 5
1
G
S M
2 8
6 0
9 5
2
G
S M
2 8
6 0
9 5
3
G
S M
2 8
6 0
9 5
4
G
S M
2 8
6 0
9 5
5
G
S M
2 8
6 0
9 5
6
G
S M
2 8
6 0
9 5
7
G
S M
2 8
6 0
9 5
8
G
S M
2 8
6 0
9 5
9
G
S M
2 8
6 0
9 6
0
G
S M
2 8
6 0
9 6
1
G
S M
2 8
6 0
9 6
2
G
S M
2 8
6 0
9 6
3
G
S M
2 8
6 0
9 6
4
G
S M
2 8
6 0
9 6
5
G
S M
2 8
6 0
9 6
6
G
S M
2 8
6 0
9 6
7
G
S M
2 8
6 0
9 6
8
G
S M
2 8
6 0
9 6
9
G
S M
2 8
6 0
9 7
0
G
S M
2 8
6 0
9 7
1
G
S M
2 8
6 0
9 7
2
G
S M
2 8
6 0
9 7
3
G
S M
2 8
6 0
9 7
4
G
S M
2 8
6 0
9 7
5
G
S M
2 8
6 0
9 7
6
G
S M
2 8
6 0
9 7
7
G
S M
2 8
6 0
9 7
8
G
S M
2 8
6 0
9 7
9
G
S M
2 8
6 0
9 8
0
G
S M
2 8
6 0
9 8
1
G
S M
2 8
6 0
9 8
2
G
S M
2 8
6 0
9 8
3
G
S M
2 8
6 0
9 8
4
G
S M
2 8
6 0
9 8
5
G
S M
2 8
6 0
9 8
6
G
S M
2 8
6 0
9 8
7
G
S M
2 8
6 0
9 8
8
G
S M
2 8
6 0
9 8
9
G
S M
2 8
6 0
9 9
0
G
S M
2 8
6 0
9 9
1
G
S M
2 8
6 0
9 9
2
G
S M
2 8
6 0
9 9
3
G
S M
2 8
6 0
9 9
4
G
S M
2 8
6 0
9 9
5
G
S M
2 8
6 0
9 9
6
G
S M
2 8
6 0
9 9
7
G
S M
2 8
6 0
9 9
8
G
S M
2 8
6 0
9 9
9
G
S M
2 8
6 1
0 0
0
G
S M
2 8
6 1
0 0
1
G
S M
2 8
6 1
0 0
2
G
S M
2 8
6 1
0 0
3
G
S M
2 8
6 1
0 0
4
G
S M
2 8
6 1
0 0
5
G
S M
2 8
6 1
0 0
6
G
S M
2 8
6 1
0 0
7
G
S M
2 8
6 1
0 0
8
G
S M
2 8
6 1
0 0
9
G
S M
2 8
6 1
0 1
0
G
S M
2 8
6 1
0 1
1
G
S M
2 8
6 1
0 1
2
G
S M
2 8
6 1
0 1
3
G
S M
2 8
6 1
0 1
4
G
S M
2 8
6 1
0 1
5
G
S M
2 8
6 1
0 1
6
G
S M
2 8
6 1
0 1
7
G
S M
2 8
6 1
0 1
8
G
S M
2 8
6 1
0 1
9
G
S M
2 8
6 1
0 2
0
G
S M
2 8
6 1
0 2
1
G
S M
2 8
6 1
0 2
2
G
S M
2 8
6 1
0 2
3
G
S M
2 8
6 1
0 2
4
G
S M
2 8
6 1
0 2
5
G
S M
2 8
6 1
0 2
6
G
S M
2 8
6 1
0 2
7
G
S M
2 8
6 1
0 2
8
G
S M
2 8
6 1
0 2
9
G
S M
2 8
6 1
0 3
0
G
S M
2 8
6 1
0 3
1
G
S M
2 8
6 1
0 3
2
G
S M
2 8
6 1
0 3
3
G
S M
2 8
6 1
0 3
4
G
S M
2 8
6 1
0 3
5
G
S M
2 8
6 1
0 3
6
G
S M
2 8
6 1
0 3
7
G
S M
2 8
6 1
0 3
8
G
S M
2 8
6 1
0 3
9
G
S M
2 8
6 1
0 4
0
G
S M
2 8
6 1
0 4
1
G
S M
2 8
6 1
0 4
2
G
S M
2 8
6 1
0 4
3
G
S M
2 8
6 1
0 4
4
G
S M
2 8
6 1
0 4
5
0%
5%
25%
50%
75%
95%
100%
Figure B.3: The plot of quantiles across arrays for GSE107080.
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Figure B.4: The plot of the first principal component (PC1) versus the second princi-
pal component (PC2) for EPIC data GSE107080. Left panel is for unadjusted data;
right panel is for adjusted data.
Next we did principal component analysis for the clean GSE107080 data set.
The results did not show any obvious patterns (see the left panel in Figure B.4).
Additionally, we regressed out the effects of age and cell type compositions and
obtained the residuals. We re-did principle component analysis on the adjusted data
and drew the plot of the first two principal components. No obvious patterns were
found in the adjusted data (see the right panel in Figure B.4).
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C Additional simulation results in Chapter 4
Table C.1: The empirical type I error rates (×100) and power (×100) for the six tests evaluated
at 5%, 1%, and 0.5% significance levels when methylation values were generated from normal
distributions without or with an outlier. The numbers of non-diseased and diseased samples are
(50, 50).
Scenarios Out Level(%) jointLRT KS AW iAW.Lev iAW.BF iAW.TM
eqM&eqV No 5 5.5 3.8 5.0 5.1 5.1 5.1
(Type I error) No 1 1.1 0.5 0.8 0.9 0.9 0.9
No 0.5 0.5 0.3 0.4 0.4 0.4 0.5
diffM&eqV No 5 75.8 68.7 77 76.3 76.6 76.6
No 1 53.1 40.8 53.5 52.9 53.2 53.6
No 0.5 42.9 40.8 44.7 43.5 44.9 43.2
eqM&diffV No 5 60.5 10.3 55.6 51.8 49.9 50.9
No 1 35.5 2.0 25.9 27.7 26.1 27.6
No 0.5 26.5 2.0 18.2 20.3 19.1 18.8
diffM&diffV No 5 49.5 30 48.8 47.2 46.3 47.0
No 1 27.1 10.0 25 23.6 23.2 23.9
No 0.5 19.0 10.0 18.4 17.3 17.6 16.8
eqM&eqV Yes 5 19.0 3.9 3.0 4.6 4.6 4.6
(Type I error) Yes 1 6.4 0.5 0.4 0.7 0.7 0.7
Yes 0.5 4.0 0.3 0.2 0.2 0.3 0.3
diffM&eqV Yes 5 64.4 72.1 84.4 81.8 82.1 81.8
Yes 1 33.9 44.3 63.9 59.7 59.5 60.0
Yes 0.5 24.3 34.9 56.7 52.2 51.5 50.0
eqM&diffV Yes 5 6.3 9.1 19.7 29.7 29.2 30.0
Yes 1 1.1 2.0 7.0 12.3 11.8 12.6
Yes 0.5 0.6 1.0 4.9 9.2 8.5 8.6
diffM&diffV Yes 5 13.9 32.6 45.8 46.1 47.2 47.3
Yes 1 3.4 11.0 23.7 23.2 24.1 24.5
Yes 0.5 1.7 7.3 18.9 18.3 19.0 18.2
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Table C.2: The empirical type I error rates (×100) and power (×100) for the six tests evaluated
at 5%, 1%, and 0.5% significance levels when methylation values were generated from Beta distri-
butions without or with an outlier. The numbers of non-diseased and diseased samples are (50,
50).
Scenarios Out Level(%) jointLRT KS AW iAW.Lev iAW.BF iAW.TM
eqM&eqV No 5 6.0 3.6 5.4 5.5 5.3 5.5
(Type I error) No 1 1.3 0.4 1.0 1.2 1.2 1.2
No 0.5 0.6 0.2 0.5 0.6 0.6 0.6
diffM&eqV No 5 73.7 70.2 77.3 75.3 76.8 76.3
No 1 50.8 41.6 54.1 50.6 51.7 50.8
No 0.5 42.1 41.6 46.0 40.9 43.0 42.2
eqM&diffV No 5 56.7 9.9 52.7 49.8 49.1 49.8
No 1 31.2 1.5 24.0 23.9 21.9 22.6
No 0.5 23.8 1.5 16.7 16.7 15.7 16.5
diffM&diffV No 5 50.5 35.2 56.8 52.2 53.7 53.8
No 1 24.6 13.1 31.2 25.7 26.8 26.8
No 0.5 17.2 13.1 23.4 17.8 20.0 19.8
eqM&eqV Yes 5 16.1 3.8 3.3 4.7 4.5 4.7
(Type I error) Yes 1 4.3 0.5 0.5 0.8 0.8 0.8
Yes 0.5 2.4 0.2 0.3 0.4 0.4 0.4
diffM&eqV Yes 5 73.8 74.2 85.5 84.1 84.9 84.2
Yes 1 48.7 46.1 65.1 61.3 62.4 61.4
Yes 0.5 37.6 46.1 55.6 51.5 50.9 51.1
eqM&diffV Yes 5 2.5 8.4 6.4 19.5 18.7 18.7
Yes 1 0.5 1.2 1.7 6.7 6.2 6.3
Yes 0.5 0.2 1.2 0.9 4.1 3.5 3.7
diffM&diffV Yes 5 2.8 28.4 13.4 10.8 10.9 10.7
Yes 1 0.7 9.7 4.8 2.4 2.5 2.4
Yes 0.5 0.4 9.7 3.2 1.4 1.4 1.4
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Table C.3: The empirical type I error rates (×100) and power (×100) for the six tests evaluated
at 5%, 1%, and 0.5% significance levels when methylation values were generated from mixtures of
two normal distributions without or with an outlier. The numbers of non-diseased and diseased
samples are (50, 50).
Scenarios Out Level(%) jointLRT KS AW iAW.Lev iAW.BF iAW.TM
eqM&eqV No 5 2.4 4 4.5 8.9 5.3 10.0
(Type I error) No 1 0.5 0.6 0.9 2.7 1.4 2.8
No 0.5 0.3 0.3 0.4 1.6 0.7 1.5
diffM&eqV No 5 9.8 29.8 44.2 26.5 49.9 27.7
No 1 2.2 10.5 20.4 7.9 23.2 10.0
No 0.5 1.1 7.0 14.8 5.0 15.0 6.3
eqM&diffV No 5 18.5 68.3 36.4 59 35.3 46
No 1 3.6 31.5 19.7 33.3 16.7 26.5
No 0.5 1.7 22.1 15.7 27.1 11.3 20.3
diffM&diffV No 5 21.2 71.9 41.1 63.6 41.6 51.2
No 1 4.8 34.4 23.6 37.7 21 30.7
No 0.5 2.3 25.6 18.3 30.3 14.9 24.6
eqM&eqV Yes 5 47.0 3.9 2.2 4.4 4.2 5.0
(Type I error) Yes 1 15.2 0.6 0.3 0.8 0.8 0.9
Yes 0.5 9.2 0.3 0.1 0.3 0.4 0.4
diffM&eqV Yes 5 3.2 31.4 11.3 10.2 39.5 15.3
Yes 1 0.5 11.2 3.2 2.6 19.8 3.9
Yes 0.5 0.3 7.4 1.8 1.7 13.0 2.5
eqM&diffV Yes 5 0.2 66.1 7.4 39.6 24.7 33.1
Yes 1 0.1 30.6 2.2 19.2 11.6 15.1
Yes 0.5 0.0 21.8 1.3 14.8 7.7 11.5
diffM&diffV Yes 5 0.3 69.8 10.6 44.9 32.8 39.4
Yes 1 0.0 34.6 3.8 24.3 16.4 20.2
Yes 0.5 0.0 25.2 2.4 19.2 11.0 15.3
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Table C.4: The empirical type I error rates (×100) and power (×100) for the six tests evaluated
at 5%, 1%, and 0.5% significance levels when methylation values were generated from Chi-square
distributions without or with an outlier. The numbers of non-diseased and diseased samples are
(50, 50).
Scenarios Out Level(%) jointLRT KS AW iAW.Lev iAW.BF iAW.TM
eqM&eqV No 5 13.8 3.7 4.8 6.1 5.1 5.1
(Type I error) No 1 5.9 0.5 0.7 1.3 1.0 0.9
No 0.5 4.3 0.2 0.4 0.8 0.5 0.5
diffM&eqV No 5 50.1 88.1 91.8 85.7 94.2 93.6
No 1 21.3 64.9 78.9 63.4 82.7 81.5
No 0.5 12.8 64.9 71.6 50.5 75.5 72.2
eqM&diffV No 5 12.0 6.9 15.9 16.3 18.5 18.3
No 1 3.4 0.9 5.2 5.3 6.2 6.3
No 0.5 2.0 0.9 3.0 3.0 3.9 3.6
diffM&diffV No 5 11.4 21.7 34.5 28.0 39.7 38.7
No 1 3.0 6.1 16.1 10.5 19 18.2
No 0.5 1.5 6.1 10.6 6.2 13.4 11.7
eqM&eqV Yes 5 23.1 3.6 3.3 6.4 5.0 5.0
(Type I error) Yes 1 12.2 0.5 0.4 1.4 0.8 0.8
Yes 0.5 9.3 0.2 0.2 0.6 0.4 0.3
diffM&eqV Yes 5 16.4 85.2 93.3 82.5 93.1 92.6
Yes 1 2.6 59.6 82.7 57.1 81.5 79.8
Yes 0.5 1.6 50.1 76.8 47.3 75.5 72.8
eqM&diffV Yes 5 19.8 6.3 19.4 24.7 24.0 23.8
Yes 1 5.6 0.7 4.4 7.9 7.9 7.5
Yes 0.5 3.6 0.4 2.5 4.6 4.9 5.0
diffM&diffV Yes 5 14.2 18.8 39.9 34.3 43.5 42.3
Yes 1 3.9 4.8 18.0 13.4 22.3 21.1
Yes 0.5 2.2 2.8 12.6 8.9 16.3 14.9
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Table C.5: The empirical type I error rates (×100) and power (×100) for the six tests evaluated
at 5%, 1%, and 0.5% significance levels when methylation values were generated from normal
distributions without or with an outlier. The numbers of non-diseased and diseased samples are
(20, 20).
Scenarios Out Level(%) jointLRT KS AW iAW.Lev iAW.BF iAW.TM
eqM&eqV No 5 5.9 3.3 5.3 5.4 5.7 5.8
(Type I error) No 1 1.4 0.4 0.9 0.9 1.2 1.0
No 0.5 0.8 0.4 0.4 0.4 0.5 0.4
diffM&eqV No 5 35.5 29.2 35.2 33.7 34.1 33.6
No 1 15.2 9.1 16.0 14.7 14.5 14.6
No 0.5 10.9 9.1 11.8 9.7 9.8 10.0
eqM&diffV No 5 25.6 4.8 19.8 19.9 17.9 18.5
No 1 8.4 0.7 4.6 6.2 4.6 5.8
No 0.5 5.4 0.7 2.6 3.4 2.6 3.2
diffM&diffV No 5 22.3 11.7 20.6 20.1 18.5 19.1
No 1 6.7 2.7 6.5 6.4 5.5 6.2
No 0.5 4.2 2.7 4.3 3.8 3.7 4.0
eqM&eqV Yes 5 26.2 3.1 2.6 3.5 3.8 3.7
(Type I error) Yes 1 10.6 0.4 0.3 0.3 0.5 0.5
Yes 0.5 7.2 0.4 0.1 0.1 0.2 0.2
diffM&eqV Yes 5 22.5 34.7 45.7 42.4 42.9 42.4
Yes 1 6.4 11.7 21.1 19.3 19.2 19.0
Yes 0.5 3.2 11.7 15.3 15.1 12.2 12.6
eqM&diffV Yes 5 0.6 4.2 8.2 9.3 9.9 10.4
Yes 1 0.1 0.5 2.1 2.9 2.9 3.1
Yes 0.5 0.1 0.5 1.3 2.1 1.8 1.9
diffM&diffV Yes 5 3.5 13.9 23.3 21.1 22.8 22.7
Yes 1 0.5 3.6 8.3 7.9 8.4 8.6
Yes 0.5 0.2 3.6 5.6 5.8 5.0 5.3
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Table C.6: The empirical type I error rates (×100) and power (×100) for the six tests evaluated
at 5%, 1%, and 0.5% significance levels when methylation values were generated from Beta distri-
butions without or with an outlier. The numbers of non-diseased and diseased samples are (20,
20).
Scenarios Out Level(%) jointLRT KS AW iAW.Lev iAW.BF iAW.TM
eqM&eqV No 5 6.2 3.3 5.4 5.5 5.5 5.7
(Type I error) No 1 1.5 0.4 0.9 0.8 1.0 1.0
No 0.5 0.8 0.4 0.3 0.3 0.5 0.4
diffM&eqV No 5 36 30.8 37.4 35.2 36.3 35.4
No 1 14.8 9.7 17.8 16.8 16.7 16.7
No 0.5 10.1 9.7 13.4 12.1 11.1 11.5
eqM&diffV No 5 22.9 4.7 18.0 18.9 16.8 17.6
No 1 7.2 0.4 4.9 6.3 4.6 5.3
No 0.5 4.7 0.4 2.6 3.9 2.6 2.9
diffM&diffV No 5 20.9 14.0 23.0 21.2 21.3 21.2
No 1 6.3 3.2 8.2 8.1 8.1 8.1
No 0.5 3.7 3.2 5.5 5.2 4.9 5.3
eqM&eqV Yes 5 23.5 3.3 2.6 3.6 4.1 4.0
(Type I error) Yes 1 6.4 0.4 0.2 0.3 0.5 0.5
Yes 0.5 3.4 0.4 0.1 0.1 0.2 0.2
diffM&eqV Yes 5 32.4 36.3 46.5 45.0 43.7 43.3
Yes 1 13.7 12.1 22.4 20.1 19.1 19.3
Yes 0.5 7.8 12.1 16.2 13.7 13.1 13.5
eqM&diffV Yes 5 0.3 4.2 3.8 4.7 5.4 5.2
Yes 1 0.0 0.3 1.1 1.3 1.6 1.7
Yes 0.5 0.0 0.3 0.5 0.8 1.1 1.1
diffM&diffV Yes 5 1.6 9.3 8.4 3.4 3.7 3.6
Yes 1 0.3 1.8 3.1 0.9 1.2 1.1
Yes 0.5 0.1 1.8 2.1 0.5 0.6 0.6
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Table C.7: The empirical type I error rates (×100) and power (×100) for the six tests evaluated
at 5%, 1%, and 0.5% significance levels when methylation values were generated from mixtures of
two normal distributions without or with an outlier. The numbers of non-diseased and diseased
samples are (20, 20).
Scenarios Out Level(%) jointLRT KS AW iAW.Lev iAW.BF iAW.TM
eqM&eqV No 5 3.4 3.3 4.5 8.1 5.1 6.7
(Type I error) No 1 0.8 0.5 0.8 2.4 1.3 1.6
No 0.5 0.5 0.5 0.4 1.3 0.6 0.9
diffM&eqV No 5 5.8 11 17.7 10.8 17.5 12.6
No 1 1.3 2 5.2 2.0 4.9 2.8
No 0.5 0.7 2 3.1 0.9 2.4 1.1
eqM&diffV No 5 11.2 24.4 26.2 28.5 23.1 27.3
No 1 2.1 5.5 13.8 11.2 10 12.2
No 0.5 0.9 5.5 10.2 6.3 6.9 7.5
diffM&diffV No 5 11.8 25.4 29.1 31.1 25.9 30.4
No 1 1.9 6.8 15.8 11.9 10.8 13.3
No 0.5 0.8 6.8 11.5 6.2 7.2 8.1
eqM&eqV Yes 5 60.5 3.4 1.9 2.9 2.2 2.3
(Type I error) Yes 1 23.6 0.5 0.2 0.5 0.3 0.3
Yes 0.5 14.2 0.5 0.1 0.2 0.1 0.1
diffM&eqV Yes 5 2.7 12.7 9.0 7.0 17.3 10.4
Yes 1 0.7 2.8 2.2 2.3 6.9 3.4
Yes 0.5 0.2 2.8 1.2 1.2 4.0 2.0
eqM&diffV Yes 5 0.3 22.8 8.4 13.6 16.0 16.4
Yes 1 0.0 5.6 2.3 5.6 7.3 7.4
Yes 0.5 0.0 5.6 1.6 3.5 5.0 5.1
diffM&diffV Yes 5 0.7 26 10.4 16.3 19.7 20.3
Yes 1 0.1 7.2 3.8 6.6 9.7 9.6
Yes 0.5 0.1 7.2 2.6 4.2 6.9 6.7
127
Table C.8: The empirical type I error rates (×100) and power (×100) for the six tests evaluated
at 5%, 1%, and 0.5% significance levels when methylation values were generated from Chi-square
distributions without or with an outlier. The numbers of non-diseased and diseased samples are
(20, 20).
Scenarios Out Level(%) jointLRT KS AW iAW.Lev iAW.BF iAW.TM
eqM&eqV No 5 13.4 3.2 5.3 6.4 5.3 5.5
(Type I error) No 1 5.2 0.4 0.9 1.3 1.0 0.9
No 0.5 3.7 0.4 0.4 0.6 0.5 0.5
diffM&eqV No 5 23.9 45.3 52.4 41.0 55.7 52.8
No 1 7.4 17.0 26.6 17.5 30.4 28.3
No 0.5 4.6 17 19.4 10.6 22.6 19.2
eqM&diffV No 5 7.7 3.9 8.7 8.8 9.2 9.2
No 1 2.0 0.6 1.7 2.2 2.2 2.4
No 0.5 1.2 0.6 1.0 1.1 1.1 1.2
diffM&diffV No 5 8.5 9.8 15.5 13.0 18.5 16.9
No 1 2.0 1.6 4.3 3.5 6.2 5.7
No 0.5 1.1 1.6 2.5 1.5 3.7 2.7
eqM&eqV Yes 5 29.7 3.0 2.7 5.9 4.0 3.8
(Type I error) Yes 1 16.1 0.4 0.3 0.7 0.7 0.5
Yes 0.5 12.3 0.4 0.1 0.2 0.3 0.2
diffM&eqV Yes 5 4.0 35.2 55.9 36.1 52.9 52.3
Yes 1 0.8 11.2 30.9 17.8 29.3 29.8
Yes 0.5 0.2 11.2 23.8 12.1 20.6 22.1
eqM&diffV Yes 5 11.9 3.6 9.1 13.3 11 12.2
Yes 1 3.6 0.4 2.1 3.9 2.3 2.9
Yes 0.5 2.0 0.4 1.0 2.1 1.0 1.3
diffM&diffV Yes 5 9.2 6.8 18.2 17.0 20.3 20.7
Yes 1 2.5 0.9 5.4 5.5 6.7 7.2
Yes 0.5 1.3 0.9 3.4 3.3 3.7 4.0
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D Parameter estimation in Chapter 5
In the first component, the miRNAs are over-variated in diseased samples, i.e.
σ21c > σ
2
1n. In the third component, the miRNAs are under-variated in diseased
samples, i.e. σ23c < σ
2
3n. Our prior belief is that the majority of miRNAs are usually
non-differentially variated, so we assume pi2 > pi1 and pi2 > pi3. We re-parameterized
variances as
sk = log(σ
2
k), k = 1c, 2, 3c, 1n, 3n. (D.1)
We re-parameterized variances again to make sure σ21c > σ
2
1n and σ
2
3c < σ
2
3n:
s1n =s1c − exp(41n),
s3n =s3c + exp(43n).
(D.2)
To make sure the covariance matrix is positive definite, the correlation ρ should
satisfies the condition
− 1
m− 1 < ρ < 1.
129
So we re-parameterized the correlation parameter
ρ =
exp(r)− 1/(m− 1)
1 + exp(r)
. (D.3)
Then the log density for miRNAs in the first cluster:
log [f1(x)|θ1] =− mc
2
log(2pi)− mc
2
s1c − mc
2
log(mc) +
mc − 1
2
log(mc − 1) + mc
2
log [1 + exp(r1c)]− r1c
2
− [a (x1c, µ1c)]
T [a (x1c, µ1c)]
2 exp(s1c)
mc − 1
mc
[1 + exp(r1c)]
+
(
[a (x1c, µ1c)]
T 1
)2 [
(mc − 2) + exp(r1c)(mc − 1)− 1exp(r1c)
]
2 exp(s1c)m2c
− mn
2
log(2pi)− mn
2
[s1c − exp(41n)]− mn
2
log(mn) +
mn − 1
2
log(mn − 1) + mn
2
log [1 + exp(r1n)]− r1n
2
− [a (x1n, µ1n)]
T [a (x1n, µ1n)]
2 exp([s1c − exp(41n)])
mn − 1
mn
[1 + exp(r1n)]
+
(
[a (x1n, µ1n)]
T 1
)2 [
(mn − 2) + exp(r1n)(mn − 1)− 1exp(r1n)
]
2 exp([s1c − exp(41n)])m2n
,
(D.4)
where
a(x, µ)Ta(x, µ) =xTx− 2µ1Tx+ nµ2,(
a(x, µ)T1
)2
=
(
1Tx
)2
+ n2µ2 − 2nµxT1.
The log density for miRNAs in the second cluster:
log [f2(x)|θ2] =− mc
2
log(2pi)− mc
2
s2 − mc
2
log(mc) +
mc − 1
2
log(mc − 1) + mc
2
log [1 + exp(r2c)]− r2c
2
− [a (x1c, µ2c)]
T [a (x1c, µ2c)]
2 exp(s2)
mc − 1
mc
[1 + exp(r2c)]
+
(
[a (x1c, µ2c)]
T 1
)2 [
(mc − 2) + exp(r2c)(mc − 1)− 1exp(r2c)
]
2 exp(s2)m2c
− mn
2
log(2pi)− mn
2
[s2]− mn
2
log(mn) +
mn − 1
2
log(mn − 1) + mn
2
log [1 + exp(r2n)]− r2n
2
− [a (x1n, µ2n)]
T [a (x1n, µ2n)]
2 exp([s2])
mn − 1
mn
[1 + exp(r2n)]
+
(
[a (x1n, µ2n)]
T 1
)2 [
(mn − 2) + exp(r2n)(mn − 1)− 1exp(r2n)
]
2 exp([s2])m2n
.
(D.5)
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The log density for miRNAs in the third cluster:
log [f3(x)|θ3] =− mc
2
log(2pi)− mc
2
s3c − mc
2
log(mc) +
mc − 1
2
log(mc − 1) + mc
2
log [1 + exp(r3c)]− r3c
2
− [a (x3c, µ3c)]
T [a (x3c, µ3c)]
2 exp(s3c)
mc − 1
mc
[1 + exp(r3c)]
+
(
[a (x3c, µ3c)]
T 1
)2 [
(mc − 2) + exp(r3c)(mc − 1)− 1exp(r3c)
]
2 exp(s3c)m2c
− mn
2
log(2pi)− mn
2
[s3c + exp(43n)]− mn
2
log(mn) +
mn − 1
2
log(mn − 1) + mn
2
log [1 + exp(r3n)]− r3n
2
− [a (x3n, µ3n)]
T [a (x3n, µ3n)]
2 exp([s3c + exp(43n)])
mn − 1
mn
[1 + exp(r3n)]
+
(
[a (x3n, µ3n)]
T 1
)2 [
(mn − 2) + exp(r3n)(mn − 1)− 1exp(r3n)
]
2 exp([s3c + exp(43n)])m2n
.
(D.6)
EM algorithm for updating the parameter sets
After the re-parameterizations, the likelihood for the complete data can be written
as
g(y1, . . . ,yp|Ψ′) =
p∏
j=1
[pi
z1j
1 f1(xj|θ′1)z1j ][piz2j2 f2(xj|θ′2)z2j ][pi1−z1j−z2j3 f3(xj|θ′3)1−z1j−z2j ].
And the log complete likelihood function is
`0(Ψ
′) =
p∑
j=1
zTj V (pi) +
p∑
j=1
zTj Uj(θ
′),
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where
zj =(z1j, z2j, 1− z1j − z2j)T ,
V (pi) =(log(pi1), log(pi2), log(1− pi1 − pi2))T ,
Uj(θ
′) =(log(f1(xj|θ′1)), log(f2(xj|θ′2)), log(f3(xj|θ′3)))T ,
θ′1 =(s1c, r1c, µ1c,41n, r1n, µ1n)T ,
θ′2 =(s2, r2c, µ2c, r2n, µ2n)
T ,
θ′3 =(s3c, r3c, µ3c,43n, r3n, µ3n)T ,
Ψ′ =(pi1, pi2, s1c, r1c, µ1c,41n, r1n, µ1n, s2, r2c, µ2c, r2n, µ2n, s3c, r3c, µ3c,43n, r3n, µ3n)T .
EM algorithm is initiated from Ψ′(0) and generates a sequence of estimates {Ψ′(t)}.
Each iteration consists of the following two step:
E-step: Evaluate Q
(
Ψ′,Ψ′(t)
)
= E [log(g(y|Ψ′)|x,Ψ′(t)].
M-step: Find Ψ′ = Ψ′(t+1) to maximize Q
(
Ψ′,Ψ′(t)
)
.
To stabilize the estimates of pik, k = 1, 2, 3, we assume that the vector of mixing
proportions (pi1, pi2, pi3)
T are Dirichlet distributed with parameters b1 = b2 = b3 = 3.
E-step:
We can obtain
Q(Ψ′,Ψ′(t)) =
p∑
j=1
[E (zj|x,Ψ′(t))]TV (pi) +
p∑
j=1
[E (zj|x,Ψ′(t))]TU(θ′).
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Denote
wj(Ψ
′(t)) = E (zj|x,Ψ′(t)) = E (zj|xj,Ψ′(t)).
The last equality is because of the independence of data points. The k-th element
of wj(Ψ
′(t)) is
wjk(Ψ
′(t)) =E (zjk|xj,Ψ′(t))
=Pr(zjk = 1|xj,Ψ′(t))
=
Pr(xj|zjk = 1,Ψ′(t))Pr(zjk = 1|Ψ′(t))
f(xj|Ψ′(t))
=
fk(xj|θ′(t)j )pi(t)k
f(xj|Ψ′(t))
,
where
f(xj|Ψ′(t)) = f1(xj|θ′(t)1 )pi(t)1 + f2(xj|θ′(t)2 )pi(t)2 + f3(xj|θ′(t)3 )[1− pi(t)1 − pi(t)2 ].
These “weights” (wjk(Ψ
′(t)), j = 1, . . . , p, k = 1, 2) are therefore the probabilities
of category membership for the j-th miRNA, conditional on xj and given that the
parameter is Ψ′(t).
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Q(Ψ′,Ψ′(t)) =
p∑
j=1
{
E (zj1|xj,Ψ′(t)) log(pi1) + E (zj2|xj,Ψ′(t)) log(pi2)
+E (1− zj1 − zj2|xj,Ψ′(t)) log(pi3)
+ E (zj1|xj,Ψ′(t)) log(f1(xj)) + E (zj2|xj,Ψ′(t)) log(f2(xj))
+E (1− zj1 − zj2|xj,Ψ′(t)) log(f3(xj))
}
=
p∑
j=1
{
wj1
(
Ψ′(t)
)
log(pi1) + wj2
(
Ψ′(t)
)
log(pi2)
+
[
1− wj1
(
Ψ′(t)
)
− wj2
(
Ψ′(t)
)]
log(1− pi1 − pi2)
+ wj1
(
Ψ′(t)
)
log(f1(xj)) + wj2
(
Ψ′(t)
)
log(f2(xj))
+
[
1− wj1
(
Ψ′(t)
)
− wj2
(
Ψ′(t)
)]
log(f3(xj))
}
.
(D.7)
M-step:
We need to maximize the following function
Q(Ψ′|Ψ′(t)) = log[ Γ(b1 + b2 + b3)
Γ(b1)Γ(b2)Γ(b3)
] + [w
(t)
1 + (b1 − 1)] log(pi1)
+ [w
(t)
2 + (b2 − 1)] log(pi2) + [w(t)3 + (b3 − 1)] log(1− pi1 − pi2)
+
3∑
k=1
p∑
j=1
w
(t)
jk log[fk(xj|θ′k)],
where
w
(t)
k =
p∑
j=1
w
(t)
jk ,
w
(t)
jk =
pikfk(xj|θ′(t)k )∑3
k=1 pikfk(xj|θ′(t)k )
,
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and the superscript (t) indicates the number of iterations. Let the first derivative be
zero, we can get
pi
(t+1)
k =
w
(t)
k + (bk − 1)
p+ b1 + b2 + b3 − 3 . (D.8)
Denote
Qk(Ψ
′|Ψ′(t)) =
p∑
j=1
w
(t)
jk log[fk(xj|θ′k)].
The first derivatives are:
∂Qk
∂θ′k
=
p∑
j=1
w
(t)
jk
∂ log[fk(xj|θ′k)]
∂θ′k
, k = 1, 2, 3.
We solve the above equations ∂Qk
∂θ′k
= 0 to obtain the update Ψ′(t+1).
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E Additional simulation results in Chapter 5
Table E.1: The p-values of two-sided Wilcoxon signed-rank tests to evaluate whether
the differences of median Jaccard indices obtained by the gs method and by each of
other methods are significant.
Method simI simII simIII simIV
L2N.pp 3.96E-18 3.96E-18 3.96E-18 3.96E-18
L2N.q 3.96E-18 3.96E-18 3.96E-18 3.96E-18
L2N.f 3.96E-18 3.96E-18 3.96E-18 3.96E-18
N3.pp 3.96E-18 3.96E-18 3.96E-18 3.96E-18
N3.q 3.96E-18 3.96E-18 3.96E-18 3.96E-18
N3.f 3.96E-18 3.96E-18 3.96E-18 3.96E-18
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Table E.2: The p-values of two-sided Wilcoxon signed-rank tests to evaluate whether the differ-
ences of median FPR obtained by the gs method and by each of other methods are significant.
Method simI simII simIII simIV
L2N.pp 8.72E-18 3.96E-18 2.02E-16 3.96E-18
L2N.q 5.72E-18 3.95E-18 2.27E-06 3.96E-18
L2N.f 2.24E-17 3.96E-18 7.16E-02 3.96E-18
N3.pp 3.94E-18 3.96E-18 9.74E-18 3.96E-18
N3.q 3.94E-18 3.95E-18 2.66E-16 3.95E-18
N3.f 3.92E-18 3.95E-18 1.14E-11 3.95E-18
Table E.3: The p-values of two-sided Wilcoxon signed-rank tests to evaluate whether the differ-
ences of median FNR obtained by the gs method and by each of other methods are significant.
Method simI simII simIII simIV
L2N.pp 3.94E-18 3.95E-18 3.95E-18 3.95E-18
L2N.q 3.95E-18 3.95E-18 3.95E-18 3.95E-18
L2N.f 3.95E-18 3.95E-18 3.95E-18 3.95E-18
N3.pp 3.93E-18 3.95E-18 3.95E-18 3.95E-18
N3.q 3.94E-18 3.95E-18 3.95E-18 3.95E-18
N3.f 3.95E-18 3.95E-18 3.95E-18 3.95E-18
Table E.4: The p-values of two-sided Wilcoxon signed-rank tests to evaluate whether the differ-
ences of median proportion of validation obtained by the gs method and by each of other methods
are significant based on 100 bootstrap samples of real data.
L2N.pp L2N.q L2N.f N3.pp N3.q N3.f
3.96E-18 4.33E-06 8.57E-08 3.96E-18 5.02E-08 2.98E-08
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